Anamorelin (ONO-7643) is a synthetic, orally active ghrelin receptor agonist developed for the treatment of cancer-related cachexia — a debilitating syndrome of involuntary weight loss, muscle wasting, and appetite loss that affects an estimated 50–80% of advanced cancer patients. Unlike endogenous ghrelin, which has a half-life of minutes, anamorelin was designed for once-daily oral administration with sustained receptor activation.[1]

Anamorelin received regulatory approval in Japan in 2021 for cancer cachexia in patients with non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, and colorectal cancer — making it one of very few peptide-derived therapeutics with a specific cachexia indication.[2] It has not been approved by the FDA or EMA, though clinical trials have been conducted in multiple countries.

Compound Profile

What Does Anamorelin Actually Do?

Anamorelin research has established it as an appetite-stimulating and anabolic agent acting through the growth hormone secretagogue receptor (GHS-R1a). In the ROMANA phase III clinical trials — the largest studies of any ghrelin agonist in cachexia — anamorelin significantly increased lean body mass and body weight compared to placebo in NSCLC patients with cachexia.[1]

The dual action profile — appetite stimulation plus growth hormone release — distinguishes anamorelin from simple appetite enhancers. By activating the same receptor as endogenous ghrelin, anamorelin simultaneously increases food intake through hypothalamic appetite circuits and stimulates growth hormone secretion through pituitary pathways, addressing both the caloric deficit and catabolic components of cachexia.[3]

How Anamorelin Works

Anamorelin acts as a selective agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), the same receptor targeted by endogenous ghrelin. GHS-R1a is a G protein-coupled receptor expressed in the hypothalamus, pituitary, and peripheral tissues. Receptor activation triggers two parallel downstream cascades.[1][3]

In the hypothalamus, GHS-R1a activation stimulates orexigenic (appetite-promoting) neurons in the arcuate nucleus, increasing NPY/AgRP signalling and suppressing anorexigenic POMC pathways. This produces sustained appetite stimulation — a critical effect in cachexia patients who experience profound anorexia.[3]

In the anterior pituitary, GHS-R1a activation on somatotrophs stimulates growth hormone (GH) release through pathways that are synergistic with, but independent of, the hypothalamic GHRH pathway. The resulting GH increase drives IGF-1 production, which in turn supports anabolic processes including protein synthesis and lean tissue maintenance. This mechanism connects anamorelin to the broader GH secretagogue peptide class that includes GHRP-2, GHRP-6, and Hexarelin.

Appetite & Weight Management Context

Anamorelin’s primary clinical application directly addresses appetite and weight management — specifically in the context of cancer-related appetite loss and involuntary weight decline. The ROMANA trials demonstrated statistically significant increases in body weight and lean body mass over 12 weeks of treatment.[1]

In the Japanese phase II trial, anamorelin at 100mg daily produced significant increases in body weight, lean body mass, and appetite scores compared to placebo in NSCLC patients. The appetite-stimulating effect was consistent and clinically meaningful, with patients reporting improved food intake and quality of life metrics related to eating.[5]

However, a critical limitation emerged across trials: while anamorelin consistently improved body composition endpoints, it did not significantly improve handgrip strength — a measure of functional muscle capacity. This dissociation between mass and function has been a central point of regulatory and clinical discussion.[1] See the Appetite & Weight Management goal page for broader context.

Muscle Growth Context

Anamorelin’s effects on lean body mass place it within the muscle growth research context, though with important caveats. The ROMANA trials showed significant lean mass gains (+0.95 to +1.15 kg over placebo at 12 weeks), which is meaningful in a catabolic disease context but distinct from hypertrophy research in healthy populations.[1]

The anabolic mechanism operates through GH/IGF-1 axis stimulation rather than direct myotropic effects. Anamorelin increases circulating GH and IGF-1 levels, which support protein synthesis and nitrogen retention — pathways shared with other GH secretagogues like GHRP-2 and Ipamorelin.[3]

The disconnect between lean mass gains and functional strength improvements is not fully explained. Hypotheses include insufficient study duration, the possibility that gained mass is not fully contractile tissue, or that neuromuscular function deficits in cachexia require different interventions. Compare with GHRP-2 and GHRP-6 for related GH secretagogue profiles, or see the Muscle Growth goal page.

Metabolic Health / Insulin Sensitivity Context

Ghrelin receptor activation has established effects on metabolic regulation, placing anamorelin within the metabolic health research context. GHS-R1a signalling influences glucose homeostasis, lipid metabolism, and energy balance through both central and peripheral pathways.[3]

In clinical trials, anamorelin’s metabolic effects have been characterised primarily through GH and IGF-1 changes rather than direct metabolic endpoints. GH elevation can affect glucose metabolism (GH is counter-regulatory to insulin), though clinically significant glucose disturbances were not reported as common adverse events in the ROMANA trials.[1]

The metabolic context of anamorelin is complex because its primary target population — cachexia patients — already has profoundly disrupted metabolism. Whether anamorelin’s metabolic effects would differ in non-cachexia contexts is unknown. See the Metabolic Health goal page for broader context.

Anamorelin Benefits

• Oral bioavailability: Unlike most peptide-based GH secretagogues that require injection, anamorelin is orally active — a significant practical advantage for chronically ill patient populations.[1]
• Clinically proven appetite stimulation: Phase III trials demonstrated significant, sustained appetite increases in cancer cachexia patients — one of very few compounds with robust clinical evidence for this indication.[1][5]
• Lean mass preservation: ROMANA trials showed significant lean body mass increases over placebo, addressing the muscle-wasting component of cachexia.[1]
• Regulatory validation: Japanese approval for cancer cachexia provides regulatory-level evidence review — a level of validation that most research peptides lack entirely.[2]
• Dual mechanism: Simultaneous appetite stimulation and GH/IGF-1 axis activation addresses both reduced intake and increased catabolism in cachexia.[3]

Anamorelin Side Effects

Anamorelin has a more established safety profile than most research peptides, thanks to Phase III clinical trial data. The ROMANA trials reported the following adverse events:

• Glycaemic effects: GH-mediated increases in blood glucose were observed. Diabetes mellitus or glucose intolerance was reported in a small percentage of patients, consistent with GH’s counter-regulatory metabolic effects.
• Hepatic effects: Transient elevations in liver enzymes (AST, ALT) were reported in some trial participants, typically mild and reversible.
• Cardiac QT effects: Anamorelin has a known QTc-prolonging potential, which contributed to regulatory concerns in markets outside Japan. A case report documented reversible ST-T segment changes associated with anamorelin use.[6]
• Gastrointestinal effects: Nausea and constipation were reported at rates modestly above placebo.
• Overall tolerability: In the ROMANA trials, discontinuation rates due to adverse events were comparable between anamorelin and placebo groups, suggesting generally acceptable tolerability.[1]

Half-Life

Anamorelin has a plasma half-life of approximately 7–12 hours, supporting once-daily oral dosing. This extended half-life compared to endogenous ghrelin (~10–30 minutes) or injectable GH secretagogues like GHRP-2 (~15–30 minutes) is a key pharmacological advantage.[3]

The oral bioavailability and sustained half-life were achieved through peptidomimetic design — anamorelin is technically a small molecule that mimics ghrelin’s receptor interaction rather than a traditional peptide. This structural approach bypasses the gastrointestinal degradation and poor absorption that limit most peptide therapeutics.

Limits of Current Evidence

• No FDA/EMA approval: Despite positive phase III trial results, anamorelin has not been approved outside Japan, partly due to concerns about the lean mass vs. function disconnect and QTc effects.
• Function gap: The consistent failure to improve handgrip strength despite lean mass gains is an unresolved limitation. Whether longer treatment durations or combination with exercise would close this gap is unknown.[1]
• Disease-specific evidence: Clinical trial data is almost entirely in cancer cachexia populations. Extrapolation to other wasting conditions or healthy populations is unsupported.
• Long-term safety unknown: Trial durations were 12–24 weeks. Long-term effects of sustained GHS-R1a agonism, particularly on glucose metabolism and cardiac conduction, require further study.
• Publication and industry bias: Anamorelin development was industry-sponsored, and trial reporting should be interpreted with standard considerations for industry-funded research.

Verdict

Anamorelin stands apart from most peptides on this site by virtue of having genuine phase III clinical trial evidence and regulatory approval — a rarity in the peptide research landscape. The ROMANA trials were well-designed, adequately powered, and met their primary endpoints for lean body mass. The Japanese regulatory approval validates both the efficacy signal and the acceptable safety profile for its indicated population.

The critical limitation — failure to translate lean mass gains into functional strength improvements — is important and honest to acknowledge. Whether this reflects a biological ceiling of ghrelin agonism, inadequate study duration, or the need for combined pharmacological and physical interventions remains an active research question. For cancer cachexia specifically, anamorelin represents the most clinically validated ghrelin-pathway intervention available.

FAQ

What is anamorelin?

Anamorelin (ONO-7643) is a synthetic, orally active ghrelin receptor agonist developed for cancer cachexia treatment. It stimulates appetite and increases lean body mass through the same receptor targeted by the endogenous hunger hormone ghrelin. It is approved in Japan for cachexia in several cancer types.

Is anamorelin approved by the FDA?

No. Anamorelin is approved only in Japan (2021) for cancer cachexia in NSCLC, gastric, pancreatic, and colorectal cancer patients. It has not received FDA or EMA approval, partly due to regulatory concerns about the dissociation between lean mass gains and functional strength improvements.

How does anamorelin differ from ghrelin?

While both activate the GHS-R1a receptor, anamorelin is a synthetic peptidomimetic with oral bioavailability and a half-life of 7–12 hours, compared to ghrelin’s half-life of approximately 10–30 minutes. Anamorelin can be taken as a once-daily oral tablet, whereas ghrelin requires injection.

What is cancer cachexia?

Cancer cachexia is a multi-organ syndrome characterised by involuntary weight loss, skeletal muscle wasting, and reduced appetite that cannot be fully reversed by conventional nutritional support. It affects an estimated 50–80% of advanced cancer patients and is associated with reduced treatment tolerance and survival.

Does anamorelin build muscle?

Clinical trials showed anamorelin increases lean body mass compared to placebo in cancer cachexia patients. However, this lean mass gain did not translate into improved handgrip strength — suggesting the relationship between mass and function is more complex than simple tissue accretion.[1]

What are the side effects of anamorelin?

Reported side effects from clinical trials include mild blood glucose elevation, transient liver enzyme increases, potential QTc prolongation, and gastrointestinal symptoms (nausea, constipation). Overall discontinuation rates due to adverse events were comparable to placebo in the ROMANA trials.

References

1. Temel JS, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016. PMID: 26906526
2. Wakabayashi H, et al. The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. J Cachexia Sarcopenia Muscle. 2021. PMID: 33382205
3. Currow DC, et al. The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia. Future Oncol. 2017. PMID: 28621564
4. Nishie K, et al. Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis. Lung Cancer. 2017. PMID: 29191597
5. Takayama K, et al. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial. Support Care Cancer. 2016. PMID: 27005463
6. Akaishi H, et al. Reversible ST-T Segment Changes Induced by Anamorelin: A Case Report. Respirol Case Rep. 2025. PMID: 41211336

Hexarelin is a synthetic hexapeptide growth hormone secretagogue (GHS) and one of the most potent compounds in the GHRP family for acute growth hormone release. Structurally related to GHRP-6 and GHRP-2, the hexarelin peptide activates the growth hormone secretagogue receptor (GHS-R1a) on pituitary somatotrophs, triggering a rapid, powerful pulse of GH secretion that exceeds the response produced by any other GHRP-class compound.[1][2]

What distinguishes hexarelin from other growth hormone releasing peptides is a dual pharmacological identity. Beyond its role as the strongest acute GH secretagogue in the GHRP family, hexarelin has demonstrated significant cardioprotective effects that operate independently of GH release — acting through CD36 scavenger receptors in cardiac tissue rather than the classical GHS-R1a pathway.[3][5] This makes hexarelin cardioprotection a unique research area that no other GHRP shares to the same degree.

The trade-off for hexarelin’s superior GH potency is pronounced desensitisation with repeated use. Unlike ipamorelin, which maintains its GH response during chronic exposure, hexarelin shows significant attenuation of GH release within weeks of continuous administration — a partial and reversible effect, but one that fundamentally shapes its research profile.[7]

Compound Profile

How Hexarelin Works

Hexarelin activates the growth hormone secretagogue receptor type 1a (GHS-R1a) — the same receptor targeted by endogenous ghrelin and other GHRPs. Imbimbo et al. (1994) established hexarelin’s dose-response profile in humans, demonstrating dose-dependent GH release with peak plasma GH concentrations reaching approximately 55 ng/mL at maximal doses — substantially higher than typical responses seen with GHRP-6 or GHRP-2.[1] Ghigo et al. (1997) provided a comprehensive review of the GHRP class, confirming that hexarelin and related growth hormone releasing peptides act through a distinct receptor pathway from GHRH analogs like sermorelin and CJC-1295.[2]

The critical mechanistic distinction for hexarelin growth hormone release is its dual-site action. At the pituitary level, GHS-R1a activation triggers intracellular calcium signalling and GH granule exocytosis. At the hypothalamic level, hexarelin stimulates endogenous GHRH release while partially overriding somatostatin’s inhibitory tone — a property that GHRH-pathway compounds do not share. This dual amplification produces the most potent acute GH pulse of any synthetic GHRP.[2]

Beyond GHS-R1a, hexarelin interacts with CD36 scavenger receptors — a non-GHS-R pathway that mediates its cardiovascular effects independently of GH secretion. Torsello et al. (2003) demonstrated that hexarelin’s cardioprotective activity in ischaemia-reperfusion models was largely mediated by CD36 interactions rather than GHS-R signalling.[5] This dual-receptor pharmacology is unique among GHRPs and represents hexarelin’s most distinctive mechanistic feature.

Recovery & Sleep Context

The recovery and sleep relevance of hexarelin centres on its potent stimulation of the GH axis. The largest natural GH pulse occurs during slow-wave sleep, driving tissue repair, protein synthesis, and glycogen replenishment. Hexarelin produces the strongest acute GH response in the GHRP class, making it a powerful research tool for studying GH-mediated recovery processes.[1][2]

The practical limitation for recovery and sleep applications is desensitisation. Rahim et al. (1998) demonstrated that chronic hexarelin therapy produced a significant and progressive decline in GH response over 16 weeks, reducing the AUC of GH release by approximately 45% compared to baseline.[7] This contrasts with ipamorelin, which maintains its GH response during sustained use. For recovery-focused research, hexarelin’s acute potency is unmatched, but sustained GH elevation requires consideration of tolerance patterns. Combining hexarelin with GHRH analogs like sermorelin or CJC-1295 may partially offset this limitation through complementary receptor-pathway stimulation.

Muscle Growth Context

The muscle growth interest in hexarelin operates through the GH → IGF-1 → anabolic signalling cascade. Sigalos and Pastuszak (2018) reviewed the GHS class comprehensively, documenting that growth hormone secretagogues increase lean body mass, decrease fat mass, and improve body composition through sustained GH-mediated anabolic effects.[8] Hexarelin’s superior acute GH potency theoretically positions it as the strongest driver of GH-mediated anabolism among GHRPs.

However, the desensitisation issue directly limits muscle growth applications. GH-mediated muscle accretion is a slow, cumulative process requiring sustained GH elevation over months. Hexarelin’s declining GH response during chronic exposure — documented clearly by Rahim et al. — means the initial potency advantage diminishes over the timescales most relevant to muscle growth.[7] This is why ipamorelin and GHRP-2, despite producing smaller acute GH pulses, may offer more consistent long-term support for muscle growth goals.

Hexarelin Cardioprotection

The most significant differentiator in hexarelin’s research profile is its cardioprotective activity — a property that operates through mechanisms independent of growth hormone release. Mao et al. (2014) provided a comprehensive review of hexarelin’s cardiovascular actions, establishing that CD36 scavenger receptors in cardiac tissue function as a specific cardiac receptor for hexarelin, mediating cardioprotective effects that are distinct from GHS-R1a-mediated GH secretion.[3]

Torsello et al. (2003) demonstrated this mechanism directly: in hypophysectomised rats (eliminating GH as a variable), hexarelin provided 60% protection against ischaemia-reperfusion damage to left ventricular end-diastolic pressure, compared to only 15% protection from ghrelin — confirming that hexarelin’s cardiac effects are largely CD36-mediated rather than GHS-R-dependent.[5]

Xu et al. (2012) extended these findings, showing that chronic hexarelin administration significantly attenuated cardiac fibrosis, left ventricular hypertrophy, and diastolic dysfunction in spontaneously hypertensive rats. The antifibrotic mechanism involved decreased collagen synthesis and accelerated collagen degradation via regulation of matrix metalloproteinases.[6] This hexarelin cardioprotection research represents a genuinely novel application that distinguishes the compound from every other GHRP in the class.

Performance Support Context

Hexarelin’s relevance to performance support is driven by its GH-axis activation and emerging cardiovascular research. GH elevation supports exercise recovery, substrate utilisation, and the maintenance of lean tissue — all relevant to performance support contexts. Hexarelin’s superior acute GH potency makes it the most powerful single-dose GHS for triggering the GH cascade that underpins performance-relevant physiological processes.[1][8]

The cardiovascular research adds a secondary performance dimension. Improved cardiac function, reduced ventricular remodelling, and antifibrotic effects — if translatable from preclinical models — could have implications for cardiovascular performance capacity.[6] However, hexarelin is a WADA prohibited substance, classified under the growth hormone secretagogue category, which limits its applicability in competitive athletic contexts.

Hexarelin Benefits

The hexarelin benefits profile is best understood through its established pharmacology and emerging research applications:

• Most potent acute GH release: Hexarelin produces the strongest single-dose GH response of any GHRP — exceeding GHRP-6, GHRP-2, and ipamorelin in peak GH concentrations.[1][2]
• Unique cardioprotective profile: CD36-mediated cardiac protection — reduced infarct size, attenuated fibrosis, and improved ventricular function — is a property no other GHRP shares to the same degree.[3][5][6]
• Dual-receptor pharmacology: Acts through both GHS-R1a (GH release) and CD36 (cardiovascular effects), providing two distinct research pathways in a single compound.
• Synergistic with GHRH analogs: Works through a complementary receptor pathway to sermorelin, CJC-1295, and tesamorelin, enabling dual-pathway GH amplification.
• Improved metabolic markers: Preclinical data suggests beneficial effects on lipid metabolism and body composition via CD36 receptor interactions.[5]
• Well-characterised pharmacokinetics: Decades of published research establishing dose-response, half-life (~70 minutes), and safety signals across multiple study designs.[1][2][8]

Hexarelin Side Effects

The hexarelin side effects profile reflects its potent but non-selective GHS-R1a activation:

• Cortisol and ACTH elevation: Korbonits et al. (1999) confirmed that hexarelin significantly stimulates the hypothalamo-pituitary-adrenal axis, producing measurable increases in both ACTH and cortisol. This effect is mediated via arginine vasopressin and is more pronounced than with ipamorelin.[4]
• Prolactin elevation: Dose-dependent prolactin increases accompany hexarelin’s GH release — a class effect shared with GHRP-6 but largely absent with ipamorelin.[4]
• Pronounced desensitisation: The most clinically significant hexarelin side effect is progressive attenuation of GH response. Rahim et al. (1998) documented approximately 45% reduction in GH release by week 16 of chronic therapy — reversible within 4 weeks of cessation.[7]
• Appetite stimulation: Moderate ghrelin-pathway activation produces appetite increase, though less pronounced than the intense hunger associated with GHRP-6.[4]
• Water retention: GH-mediated fluid retention, dose-dependent and reversible. Standard across the GHS class.
• WADA prohibited: Classified as a prohibited substance under World Anti-Doping Agency guidelines (GHS category).

Half-Life

Hexarelin has a plasma half-life of approximately 70 minutes — significantly longer than GHRP-6 (~15–20 minutes) and shorter than ipamorelin (~2 hours). Imbimbo et al. (1994) documented that peak GH concentrations occur approximately 30 minutes after administration, with GH levels returning to baseline within 240 minutes.[1] This produces a defined, pulsatile GH response that preserves natural secretory rhythms and somatostatin-mediated feedback.

For comparison across GH-axis peptides: sermorelin has a half-life of ~10–20 minutes, CJC-1295 without DAC ~30 minutes, and CJC-1295 with DAC extends to 5–8 days. Hexarelin’s intermediate half-life balances a potent acute pulse with reasonable duration of action. The downstream effects — IGF-1 elevation, lipolysis, tissue repair signalling — operate on substantially longer timescales than the compound’s circulating presence.

Limits of Current Evidence

• Not approved anywhere: Hexarelin has never received regulatory approval for any indication in any jurisdiction. Unlike tesamorelin (FDA-approved) or semaglutide (FDA-approved), hexarelin remains exclusively a research compound.
• Desensitisation limits chronic utility: The progressive decline in GH response during sustained use is a fundamental limitation that distinguishes hexarelin from compounds like ipamorelin that maintain efficacy.[7]
• Cardioprotective data is preclinical: The CD36-mediated cardiac protection — while consistent across multiple animal models — has not been validated in human cardiac outcome studies.[3][5][6]
• Cortisol and prolactin elevation: Non-selective HPA axis stimulation positions hexarelin below ipamorelin and GHRP-2 on the selectivity spectrum.[4]
• Limited large-scale human RCTs: Most published hexarelin studies are characterisation or mechanism studies. Therapeutic-scale randomised controlled trials are absent.
• Long-term safety data is sparse: The longest published human study spans 16 weeks. Multi-year safety profiles are not established.[7]

Verdict

This hexarelin review positions the compound as a paradox within the GHRP class: the most potent acute GH secretagogue, yet the most prone to desensitisation with sustained use. For single-dose GH release potency, no other growth hormone releasing peptide matches hexarelin’s documented peak — a pharmacological fact established across multiple clinical studies.[1][2][8]

The desensitisation profile fundamentally shapes hexarelin’s practical positioning. Where ipamorelin and GHRP-2 maintain their GH response over weeks and months, hexarelin’s efficacy declines significantly within the first month of chronic exposure.[7] This limits its utility for applications requiring sustained GH elevation — including most recovery, sleep, and muscle growth contexts.

Where hexarelin holds a genuinely unique position is in cardiovascular research. The CD36-mediated cardioprotective effects — reduced infarct size, attenuated fibrosis, improved ventricular function — represent a pharmacological property that no other GHRP demonstrates to the same degree.[3][5][6] If these preclinical findings translate to human models, hexarelin may ultimately be remembered more for its cardiac applications than for its role as a GH secretagogue. For now, evaluate hexarelin as the most potent but least sustainable GHRP for GH release, with an intriguing and potentially transformative cardiovascular research frontier.

FAQ

What is hexarelin?

Hexarelin is a synthetic hexapeptide growth hormone secretagogue that activates the GHS-R1a receptor, producing the most potent acute GH release of any compound in the GHRP family. It also acts on CD36 scavenger receptors in cardiac tissue, producing cardioprotective effects independent of GH secretion. Hexarelin is not approved by any regulatory agency and remains a research compound.[1][3]

How does hexarelin differ from other GHRPs?

Hexarelin produces the strongest acute GH pulse of any GHRP but also shows the most pronounced desensitisation with repeated use. It uniquely demonstrates CD36-mediated cardioprotective effects that other GHRPs like ipamorelin and GHRP-6 do not share to the same degree. It also stimulates cortisol and prolactin, placing it lower on the selectivity spectrum than ipamorelin.[2][4][7]

Does hexarelin cause desensitisation?

Yes — hexarelin shows significant desensitisation during chronic use. Rahim et al. (1998) documented approximately 45% reduction in GH response by week 16 of continuous therapy. The desensitisation is partial and reversible, with GH response returning to baseline within 4 weeks of cessation.[7]

What are hexarelin’s cardioprotective effects?

Hexarelin cardioprotection operates through CD36 scavenger receptors in cardiac tissue, independently of GH release. Preclinical research has demonstrated reduced ischaemia-reperfusion damage, attenuated cardiac fibrosis, decreased left ventricular hypertrophy, and improved diastolic function in animal models.[3][5][6]

Does hexarelin affect cortisol?

Yes. Korbonits et al. (1999) confirmed that hexarelin significantly stimulates ACTH and cortisol release via arginine vasopressin-mediated HPA axis activation. This effect is transient but measurable, and distinguishes hexarelin from more selective compounds like ipamorelin that do not affect cortisol.[4]

Is hexarelin FDA approved?

No. Hexarelin has never received FDA approval or regulatory approval in any jurisdiction. It remains exclusively a research compound. It is also classified as a WADA prohibited substance under the growth hormone secretagogue category. For FDA-approved GH-axis compounds, see tesamorelin.

How does hexarelin compare to ipamorelin for research?

Hexarelin produces a substantially stronger acute GH pulse but desensitises with chronic use, while ipamorelin maintains its GH response over time. Ipamorelin is more selective, avoiding cortisol and prolactin elevation. Hexarelin’s unique advantage is its CD36-mediated cardioprotective profile, which ipamorelin does not demonstrate.[1][3][7]

References

1. Imbimbo BP, et al. Growth hormone-releasing activity of hexarelin in humans. A dose-response study. Eur J Clin Pharmacol. 1994;46(5):421-425. PMID: 7957536
2. Ghigo E, et al. Growth hormone-releasing peptides. Eur J Endocrinol. 1997;136(5):445-460. PMID: 9186261
3. Mao Y, Tokudome T, Kishimoto I. The cardiovascular action of hexarelin. J Geriatr Cardiol. 2014;11(3):253-258. PMID: 25278975
4. Korbonits M, et al. The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. J Clin Endocrinol Metab. 1999;84(7):2489-2495. PMID: 10404825
5. Torsello A, et al. Ghrelin plays a minor role in the physiological control of cardiac function in the rat. Endocrinology. 2003;144(5):1787-1792. PMID: 12697684
6. Xu X, et al. Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol. 2012;303(6):H703-H711. PMID: 22842067
7. Rahim A, O’Neill PA, Shalet SM. Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab. 1998;83(5):1644-1649. PMID: 9589671
8. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28400207

Medical Disclaimer: This page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Hexarelin is not approved by the FDA or any regulatory agency for any indication. Always consult a qualified healthcare professional before making any decisions related to your health. The information presented reflects published research and does not imply endorsement of any compound for human use outside of supervised clinical settings.

GHRP-6 (growth hormone releasing peptide 6), also commonly written as GHRP 6, is a synthetic hexapeptide and one of the earliest growth hormone secretagogues (GHS) developed for research. Originally characterised by Cyril Bowers’ group, GHRP-6 peptide (also known as the GHRP 6 peptide) mimics ghrelin’s action on the growth hormone secretagogue receptor (GHS-R1a), triggering potent pulsatile growth hormone release from the anterior pituitary. It belongs to the same receptor-pathway family as GHRP-2 and ipamorelin, but with a distinctly different selectivity profile.

What distinguishes GHRP-6 from more selective GH secretagogues is its broader hormonal footprint. Unlike ipamorelin — described as the first selective GH secretagogue — GHRP-6 also stimulates cortisol, ACTH, and prolactin release, and produces strong appetite stimulation via the ghrelin pathway.[1][4] This lower selectivity positioned GHRP-6 as a foundational research tool rather than a refined therapeutic candidate, but its decades of published data make it one of the most thoroughly characterised compounds in the GHS class.

GHRP-6 holds particular historical significance: it was instrumental in the discovery and characterisation of the ghrelin/GHS-R pathway itself.[1] More recently, emerging cardioprotective research has generated renewed interest in this compound beyond its original GH-releasing applications.[7][8]

Compound Profile

What Does GHRP-6 Actually Do?

GHRP 6 is fundamentally a GH-axis activator that works through the ghrelin receptor, producing one of the strongest acute GH responses among synthetic secretagogues. When it binds GHS-R1a on pituitary somatotroph cells, it triggers a rapid, potent pulse of growth hormone release — the defining pharmacological action that made it a cornerstone of early GHS research.[1][2]

Beyond GH release, GHRP-6 produces notable secondary effects that distinguish it from more selective compounds in the same class. The most prominent is strong appetite stimulation — a direct consequence of activating the ghrelin receptor in the hypothalamic arcuate nucleus. This orexigenic effect is substantially more pronounced than with GHRP-2 and largely absent with ipamorelin.[1][4] GHRP-6 also elevates cortisol, ACTH, and prolactin — hormonal cross-talk that cleaner secretagogues avoid.

An unexpected area of renewed interest is GHRP-6’s emerging cardioprotective profile. Preclinical research has demonstrated protective effects against doxorubicin-induced myocardial damage and post-infarct ventricular remodelling, suggesting mechanisms beyond simple GH secretion.[7][8] This represents a potentially significant second chapter for a compound that many had assumed was fully characterised.

How GHRP-6 Works

GHRP-6 activates the growth hormone secretagogue receptor type 1a (GHS-R1a) — the same receptor targeted by endogenous ghrelin. Bowers (1998) provided the foundational review of GHRP 6 growth hormone releasing activity and GHRP-6’s mechanism, documenting how it triggers intracellular calcium signalling and phospholipase C activation in anterior pituitary somatotrophs, leading to rapid GH granule exocytosis.[1] Ghigo et al. (1997) further characterised the GH-releasing peptide class, establishing the dose-response and receptor-binding profiles that differentiate GHS-R1a agonists from GHRH-pathway compounds like sermorelin and CJC-1295.[2]

The key mechanistic distinction: GHRP-6 works through the ghrelin receptor, not the GHRH receptor. This means it can partially override somatostatin’s inhibitory tone on GH release — a property that GHRH analogs do not share. It also acts at the hypothalamic level, stimulating endogenous GHRH release and creating a dual-level amplification effect on GH secretion. Sinha et al. (2020) reviewed the role of growth hormone secretagogues in body composition management, contextualising GHRP-6 within the broader GHS therapeutic landscape.[3]

Where GHRP-6 diverges from more selective secretagogues is its off-target receptor activity. Oliveira et al. (2003) demonstrated that GHRP-6 stimulates cortisol and ACTH release, confirming broader hypothalamic-pituitary activation beyond the GH axis alone.[4] This contrasts with ipamorelin, which achieves comparable GH release without affecting cortisol, prolactin, or aldosterone. GHRP-2 sits between the two — more selective than GHRP-6 but less so than ipamorelin — creating a clear selectivity spectrum within the GHRP family.

Recovery & Sleep Context

The recovery and sleep interest in GHRP-6 is driven by its potent stimulation of the GH axis. The largest natural GH pulse occurs during slow-wave (deep) sleep, and GH secretagogues amplify this pulse, supporting tissue repair, protein synthesis, and glycogen replenishment during the recovery window.[1] GHRP-6’s strong acute GH response makes it one of the most potent tools in the secretagogue class for driving recovery-relevant GH elevation.

The trade-off compared to cleaner secretagogues like ipamorelin is the cortisol and appetite cross-talk. Cortisol elevation — even transient — can theoretically impair sleep architecture, and appetite stimulation is counterproductive for evening use. This is why ipamorelin and, to a lesser extent, GHRP-2 are generally preferred in recovery and sleep contexts. GHRP-6’s recovery value is strongest when synergised with GHRH analogs like sermorelin or CJC-1295, which stimulate GH through the complementary GHRH receptor pathway for amplified pulsatile release.

Muscle Growth Context

The muscle growth relevance of GHRP-6 operates through the GH → IGF-1 → anabolic signalling cascade. Camanni et al. (1998) reviewed growth hormone-releasing peptides and their analogs comprehensively, establishing the pharmacological basis for GH secretagogue-mediated anabolic effects including nitrogen retention, protein turnover, and IGF-1-driven muscle protein synthesis.[5] Micic et al. (1993) specifically characterised GHRP-6’s regulation of GH secretion, documenting the dose-response and temporal profile of GH release that underpins its anabolic potential.[6]

GHRP-6’s strong appetite stimulation — often considered a side effect — can be contextually beneficial for muscle growth goals. In caloric surplus contexts where eating enough is the limiting factor, the ghrelin-mediated hunger drive supports the energy availability that muscle accretion requires. This is a genuine pharmacological advantage that more selective compounds like ipamorelin do not provide.

The honest framing: GH-mediated muscle growth is slow and cumulative, operating over months rather than producing acute hypertrophy. GHRP-6 is positioned as a GH-axis support tool for the muscle growth environment, not a primary anabolic driver. Its value scales with training consistency, nutritional adequacy, and protocol duration.

Cardioprotective Research Context

The most unexpected chapter in GHRP-6’s research profile is its emerging cardioprotective activity — an area entirely distinct from its original GH-releasing applications. Berlanga-Acosta et al. (2024) demonstrated that GHRP-6 prevents doxorubicin-induced myocardial and extra-myocardial damages in preclinical models, identifying prosurvival mechanism activation as the likely pathway.[7] Wang et al. (2026) extended this work, showing that GHRP-6 ameliorates post-infarct ventricular remodelling and systolic dysfunction.[8]

These cardioprotective effects appear to operate through mechanisms partially independent of GH secretion — potentially involving direct GHS-R1a signalling in cardiac tissue and activation of anti-apoptotic pathways. This represents a research frontier for GHRP-6 that could differentiate it from other GH secretagogues if further validated. The data is currently preclinical and early-stage, but the consistency of findings across multiple cardiac injury models warrants attention from the research community.

GHRP-6 Benefits

The GHRP-6 benefits profile — covering all key GHRP 6 benefits — is best understood through both its established GH-releasing role and its emerging research applications:

• Potent GH secretagogue: One of the strongest acute GH responses among synthetic secretagogues — well-replicated across multiple study designs and populations.[1][2]
• Extensively characterised pharmacology: Decades of published research establishing dose-response, receptor binding, pharmacokinetics, and safety signals — one of the most studied GHRPs in the literature.[1][5][6]
• Strong appetite stimulation: Ghrelin-mediated hunger drive can be contextually beneficial for recovery and caloric surplus contexts where energy intake is a limiting factor.
• Emerging cardioprotective data: Preclinical evidence of myocardial protection and ventricular remodelling prevention represents a novel and potentially significant application.[7][8]
• Synergistic with GHRH analogs: Works through a different receptor pathway than sermorelin, CJC-1295, and tesamorelin, enabling dual-pathway GH amplification.
• Historical research significance: Instrumental in the discovery and characterisation of the ghrelin/GHS-R pathway — foundational to the entire GH secretagogue field.[1]

GHRP-6 Side Effects

The GHRP-6 side effects profile (the most commonly reported GHRP 6 side effects are listed below) reflects its lower selectivity compared to newer GH secretagogues:

• Intense appetite increase: The most consistently reported effect — direct ghrelin-pathway activation produces strong hunger drive. Substantially more pronounced than GHRP-2 and largely absent with ipamorelin.[1][4]
• Cortisol elevation: Transient but measurable cortisol and ACTH increases post-administration, confirmed by Oliveira et al. (2003). More pronounced than with GHRP-2 or ipamorelin.[4]
• Prolactin elevation: Small transient increases — clinically relevant primarily at high or chronic exposure levels.
• Water retention: GH-mediated fluid retention, dose-dependent and reversible. Standard across the secretagogue class.
• Transient flushing: Brief warmth or redness shortly after administration, typically self-resolving within minutes.
• WADA prohibited: Classified as a prohibited substance under World Anti-Doping Agency guidelines.

The GHRP-6 side effects trade-off is the central reason the research community has largely moved toward more selective compounds. The GHRP-6 vs ipamorelin comparison illustrates this clearly: comparable GH output but with significantly more hormonal cross-talk from GHRP-6. The GHRP-6 vs GHRP-2 comparison (often searched as GHRP 6 vs GHRP 2) is closer, with GHRP-2 offering modestly better selectivity while still producing appetite and cortisol effects.[1][2][4]

Half-Life

GHRP-6 has a plasma half-life of approximately 15–20 minutes — characteristic of the short-acting GHRP class. The compound triggers a rapid, defined GH pulse rather than sustained elevation: peak GH occurs within 15–30 minutes of administration, returning to baseline within 2–3 hours. This pulse-type pharmacokinetic profile preserves the body’s natural pulsatile GH secretory rhythm and somatostatin-mediated feedback.

For comparison across GH-axis peptides: sermorelin has a similar ~10–20 minute half-life, while ipamorelin extends to approximately 2 hours. CJC-1295 without DAC is ~30 minutes, while CJC-1295 with DAC extends to 5–8 days. GHRP-6’s short half-life means its downstream effects — IGF-1 elevation, lipolysis, tissue repair signalling — operate on substantially longer timescales than the compound’s circulating presence.

Limits of Current Evidence

• Not FDA approved: GHRP-6 has never pursued regulatory approval for any indication. Unlike tesamorelin (FDA-approved GHRH analog) or semaglutide and liraglutide (FDA-approved GLP-1 agonists), GHRP-6 remains a research-only compound.
• Selectivity limitations: Cortisol, ACTH, and prolactin stimulation are well-documented trade-offs that position GHRP 6 below ipamorelin and GHRP-2 on the selectivity spectrum.
• Clinical data is predominantly diagnostic/characterisation: Most published GHRP-6 studies were designed to characterise the GH-releasing mechanism rather than evaluate therapeutic outcomes. Large-scale therapeutic RCTs are absent.
• Cardioprotective data is preclinical: The emerging cardiac protection findings are promising but limited to animal models. Human cardiac outcome data does not exist.
• Superseded by newer compounds: The research community has largely moved toward more selective GH secretagogues (ipamorelin, GHRP-2) for contemporary investigation, reducing the flow of new GHRP-6-specific data.
• Long-term safety data is limited: Most studies span weeks to months. Multi-year safety profiles are not established.

Verdict

GHRP 6 holds genuine historical significance as one of the pioneering growth hormone secretagogues that helped characterise the ghrelin/GHS-R pathway — foundational work that enabled the development of every subsequent GH secretagogue including GHRP-2 and ipamorelin. Its potent GH-releasing activity is thoroughly documented across decades of published research, establishing a pharmacological profile that remains one of the most complete in the peptide literature.[1][2][5][6]

The limitation that defines GHRP-6’s contemporary positioning is selectivity. The cortisol, prolactin, and intense GHRP-6 appetite (GHRP 6 appetite) stimulation that accompany its GH release have seen it largely superseded by cleaner alternatives in modern research contexts. For recovery and sleep and muscle growth applications, ipamorelin and GHRP-2 generally offer more favourable benefit-to-side-effect profiles.

The emerging cardioprotective data represents an unexpected and potentially significant second life for this compound.[7][8] If preclinical cardiac findings translate to human models, GHRP-6 may find a distinct research niche that its more selective cousins do not occupy. For now, evaluate GHRP-6 as a well-characterised but less selective GH secretagogue with an intriguing new research frontier.

FAQ

What is GHRP-6?

For those asking what is GHRP 6: GHRP-6 (growth hormone releasing peptide 6) is a synthetic hexapeptide that stimulates growth hormone release by activating the ghrelin receptor (GHS-R1a). It was one of the earliest GH secretagogues developed and played a key role in characterising the ghrelin/GHS-R pathway. It is not FDA-approved and remains a research compound.[1]

What is the difference between GHRP-6 and GHRP-2?

Both are GHSR agonists that stimulate GH release, but GHRP-6 produces stronger appetite stimulation, greater cortisol elevation, and more prolactin increase than GHRP-2. GHRP-2 is generally considered more potent for GH release with fewer off-target effects, placing it in the middle of the selectivity spectrum between GHRP-6 and ipamorelin.[1][4]

Does GHRP-6 increase appetite?

Yes — substantially. GHRP-6 appetite stimulation is one of its most prominent and consistent effects, driven by direct activation of the ghrelin receptor in the hypothalamic appetite centre. This is markedly stronger than the appetite effects seen with GHRP-2 and largely absent with ipamorelin.[1][4]

Does GHRP-6 affect cortisol?

Yes. Oliveira et al. (2003) confirmed that GHRP-6 stimulates cortisol and ACTH release. The elevation is transient, returning to baseline within 60–90 minutes, but it is a pharmacologically significant distinction from more selective GH secretagogues like ipamorelin that do not affect cortisol.[4]

How does GHRP-6 compare to ipamorelin?

GHRP-6 produces potent GH release comparable to ipamorelin, but with significantly more off-target effects: strong appetite stimulation, cortisol elevation, ACTH increase, and prolactin elevation. Ipamorelin achieves similar GH output with minimal hormonal cross-talk, making it the more selective option. GHRP-6’s advantage is its extensively characterised research profile and emerging cardioprotective data.[1][7]

Is GHRP-6 FDA approved?

No. GHRP-6 has never received FDA approval for any indication. It remains a research compound without a regulatory approval pathway. For FDA-approved GH-axis compounds, see tesamorelin. GHRP-6 is also classified as a WADA prohibited substance.

What is GHRP-6 used for in research?

GHRP-6 is used in research settings primarily as a GH secretagogue for studying GH-axis physiology, ghrelin receptor signalling, appetite regulation, and body composition. More recently, it has been investigated for cardioprotective properties, including prevention of doxorubicin-induced myocardial damage and amelioration of post-infarct ventricular remodelling.[1][7][8]

References

1. Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316-1329. PMID: 9893708
2. Ghigo E, et al. Growth hormone-releasing peptides. Eur J Endocrinol. 1997;136(5):445-460. PMID: 9186261
3. Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. PMID: 32257855
4. Oliveira JH, et al. GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing’s disease. J Endocrinol Invest. 2003;26(3):253-258. PMID: 12809173
5. Camanni F, et al. Growth hormone-releasing peptides and their analogs. Front Neuroendocrinol. 1998;19(1):47-72. PMID: 9465289
6. Micic D, et al. Regulation of growth hormone secretion by the growth hormone releasing hexapeptide (GHRP-6). J Pediatr Endocrinol. 1993;6(3-4):283-289. PMID: 7920995
7. Berlanga-Acosta J, et al. Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages. Front Pharmacol. 2024;15:1389311. PMID: 38873418
8. Wang L, et al. GHRP-6 Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction. Pharmaceuticals. 2026;19(3). PMID: 41901314

Medical Disclaimer: This page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. GHRP-6 is not approved by the FDA for any indication. Always consult a qualified healthcare professional before making any decisions related to your health. The information presented reflects published research and does not imply endorsement of any compound for human use outside of supervised clinical settings.

GHRP-2 (growth hormone releasing peptide 2), also known as pralmorelin, is a synthetic hexapeptide that stimulates growth hormone secretion through the ghrelin/GHSR pathway. It belongs to the growth hormone secretagogue (GHS) class — mechanistically distinct from GHRH-pathway compounds like sermorelin and tesamorelin, which act on the GHRH receptor instead.

The GHRP-2 peptide was one of the earliest synthetic GH secretagogues studied in clinical settings. While never reaching FDA approval, it has a substantial body of published research — enough to establish its pharmacological profile and differentiate it from related compounds like GHRP-6 and ipamorelin. GHRP-2 acetate is the most common salt form used in research. This page should be read alongside the GHRP-2 vs Ipamorelin comparison and the Research hub.

Compound Profile

What Does GHRP-2 Actually Do?

GHRP-2 is best interpreted as a GH-axis activator through the ghrelin receptor, with appetite and hormonal cross-talk that GHRH-pathway compounds do not produce. The practical question is whether cumulative GH elevation over weeks shifts body-composition and recovery trajectories.

Useful markers from the published data:

• GH secretion: Potent, reliable pulsatile GH release — GHRP-2 produces one of the strongest GH responses among synthetic secretagogues in comparative studies.[1][2]
• Body composition trend: Increased lean mass and reduced adiposity observed in chronic administration studies. GH-mediated lipolysis drives the fat component.
• Appetite stimulation: Ghrelin-receptor activation triggers orexigenic signalling — a pharmacological feature, not a side effect. Relevant context for study design.
• Sleep architecture: GH secretagogues enhance slow-wave sleep — the phase where endogenous GH release is highest.

For users asking what does GHRP-2 do — it is fundamentally a GH-axis activator through the ghrelin pathway. Trend-based evaluation over months, not single-dose impressions. The GHRP-2 effects that matter for body composition require sustained protocols.[1][3]

How GHRP-2 Works

GHRP-2 activates the growth hormone secretagogue receptor (GHSR-1a) — the same receptor targeted by endogenous ghrelin. This triggers a signalling cascade in anterior pituitary somatotrophs that releases stored GH in a pulsatile pattern.[1][2]

The key distinction from GHRH-pathway compounds like sermorelin and CJC-1295: GHRP-2 works through the ghrelin receptor, not the GHRH receptor. This means it partially overrides somatostatin’s inhibitory tone on GH release — a property GHRH analogues do not share. It also explains the appetite cross-talk, since GHSR-1a is expressed in the hypothalamic arcuate nucleus (appetite centre).

GHRP-2 also acts at hypothalamic level, stimulating endogenous GHRH release — creating a dual-level amplification effect. This mechanism is shared across the GHRP family but with different selectivity profiles. GHRP-2 sits between GHRP-6 (strongest appetite/cortisol effects) and ipamorelin (most selective, minimal off-target). Understanding the GHSR pathway is essential context for evaluating any ghrelin-mimetic.

Recovery & Sleep Context

The recovery and sleep interest is driven by GH’s role in slow-wave sleep architecture and tissue repair. GHRP-2 enhances the natural GH pulse that occurs during deep sleep phases — the same phase where endogenous GH release is highest. This is well-established for the GH secretagogue class generally, not GHRP-2-specific, but GHRP-2 produces one of the strongest acute GH responses in the class.[1]

Sleep quality improvement is often the first subjectively noticed change in research settings — reported within the first week of consistent administration. The mechanism is straightforward: augmented slow-wave GH pulses support the recovery processes that depend on deep sleep. This is distinct from sedative sleep aids — the effect is on sleep architecture quality, not onset or duration.

Recovery capacity from physical stress operates on longer timescales. GH-mediated tissue repair, collagen synthesis, and protein turnover are downstream effects that accumulate over weeks. The confidence gap: while the GH-release mechanism is robust, dedicated recovery-outcome studies using GHRP-2 specifically are limited. The recovery framing rests on well-established GH physiology applied to a potent GH secretagogue — mechanistically sound but not confirmed in controlled recovery-specific trials.

Body Recomp Context

Body recomp framing with GHRP-2 centres on its GH-axis activation: lipolytic effects combined with lean mass preservation. Chronic administration studies show directional body-composition improvement — fat reduction without proportional lean mass loss. The GH-mediated lipolysis component is well-supported; the lean mass preservation is a consistent secondary finding.[1][3]

The appetite stimulation is the key consideration for recomp contexts. Unlike GHRH-pathway compounds like sermorelin and tesamorelin, GHRP-2 increases hunger via ghrelin signalling — which can work for or against recomp goals depending on the research context and caloric control variables. This is the core selectivity trade-off within the secretagogue class: more potent GH release, but with appetite drive that GHRH-pathway compounds avoid.

Confidence is moderate. The body-composition trends are directionally consistent across studies, but the trial sizes and durations are smaller than the GLP-1 agonist literature (e.g., semaglutide, tirzepatide). The recomp framing is mechanistically defensible — not clinically proven at the same depth.

Performance Support Context

The performance support read is based on GH-mediated recovery enhancement and lean mass trends. GHRP-2 does not directly enhance performance — it shifts the physiological context in which recovery and adaptation occur. The mechanism is indirect: augmented GH pulses support protein synthesis, tissue repair, and sleep quality, all of which feed into training adaptation capacity.

The relevance is strongest for recovery-dependent performance contexts — where the rate-limiter is recovery between training sessions rather than acute output. This is consistent with how other GH secretagogues in the class are positioned for performance support.

The honest limitation: no controlled trials have measured GHRP-2’s impact on specific performance outcomes (strength, endurance, power). The performance-support framing is an extrapolation from GH physiology, not a directly demonstrated effect. Evaluate as a recovery-context tool, not a performance enhancer.

Muscle Growth Context

The muscle growth interest in GHRP-2 is driven by GH’s established role in protein synthesis and lean mass maintenance. GH-axis activation supports the anabolic environment — nitrogen retention, protein turnover, and IGF-1 elevation — that underpins muscle tissue accretion.[1][3]

What the data supports: chronic GH secretagogue administration produces lean mass preservation and modest lean mass trends in the positive direction. What it does not support: dramatic hypertrophy comparable to anabolic agents. GH-mediated muscle growth is a slow, cumulative process that operates over months, not the acute effect profile users may expect.

The practical context is that GHRP-2 is positioned as a GH-axis support tool for muscle growth environments, not a primary growth driver. The appetite stimulation (unique to the GHRP class vs GHRH-pathway compounds) can support caloric surplus contexts where eating enough is a limiting factor — an indirect but relevant consideration for muscle growth goals.

GHRP-2 Benefits

Most GHRP-2 peptide benefits discussion is strongest when anchored to published evidence:

• Potent GH release: Among the strongest GH responses of any synthetic secretagogue — replicated across multiple studies.[1][2]
• Body composition improvement: Lean mass preservation and fat reduction trends in chronic administration data.
• Sleep architecture enhancement: Slow-wave sleep improvement — the GH-relevant sleep phase.
• Synergistic stacking potential: GHSR + GHRH-pathway compounds produce amplified GH output beyond either agent alone — well-documented pharmacological synergy.[3]
• Established research profile: Decades of published data establishing pharmacokinetics, safety signals, and dose-response relationships.

Confidence scales with study quality. The GH-release data is robust. Body-composition extrapolations are mechanistically sound but drawn from smaller or shorter-duration studies than the GLP-1 agonist literature.[1][2][3]

GHRP-2 Side Effects

For GHRP-2 side effects, the published data provides a well-characterised profile:

• Increased appetite: The most consistently reported effect — direct ghrelin-pathway signalling. Dose-dependent. This distinguishes GHRP-2 from cleaner secretagogues like ipamorelin.
• Cortisol elevation: Mild, transient increases post-administration. Returns to baseline within 60–90 minutes. More pronounced than ipamorelin, less than GHRP-6.[2]
• Prolactin elevation: Small transient increase — clinically relevant only at chronic high doses or in individuals with pre-existing sensitivity.
• Water retention: GH-mediated fluid retention. Dose-dependent, reversible.
• Injection site reactions: Localised redness or irritation. Standard peptide-class effect.
• Paraesthesia: Tingling in extremities. A known GH-pathway effect, not GHRP-2-specific.

The GHRP-2 benefits and side effects trade-off is what positions it within the secretagogue class: stronger GH output than ipamorelin, but with more hormonal cross-talk. GHRP-2 peptide side effects are generally manageable at standard research concentrations — log consistently and distinguish GH-class effects from compound-specific ones.[1][2]

Half-Life

Plasma half-life of approximately 15–25 minutes following subcutaneous or intravenous administration. The short half-life is characteristic of the GHRP class — the compound triggers a GH pulse rather than sustained elevation. Peak GH occurs 15–30 minutes post-administration, returning to baseline within 2–3 hours. Downstream effects (IGF-1 elevation, lipolysis) operate on longer timescales than GHRP-2’s circulating presence.

Limits of Current Evidence

• GH-release data is robust — replicated across multiple study designs and populations.[1][2]
• Body-composition data is directional but limited — smaller studies and shorter durations than the GLP-1 agonist literature.
• No FDA approval — unlike tesamorelin (GHRH pathway) or liraglutide/semaglutide (GLP-1 pathway).
• No head-to-head RCTs against ipamorelin — the most common comparison is based on mechanistic inference, not direct clinical data.
• Long-term safety data is limited — most studies are weeks to months, not years.

Verdict

GHRP-2 has genuine research credentials — decades of published data establishing it as one of the most potent GH secretagogues available. The pharmacological profile is well-characterised: strong GH release through the ghrelin receptor, with appetite stimulation and mild hormonal cross-talk as trade-offs.

The limitation is evidence depth for body-composition outcomes specifically. The GH-release mechanism is proven; the downstream body-composition claims rest on smaller studies and mechanistic inference rather than large RCTs. Honest positioning: GHRP-2 is a well-studied GH-axis tool with established pharmacology, not a clinically validated body-composition intervention.

If you are evaluating fit, anchor against Recovery & Sleep, Body Recomp, and Performance Support goal context, then pressure-test with GHRP-2 vs Ipamorelin and GHRP-2 vs GHRP-6.

FAQ

What is GHRP-2 used for in research?

GHRP-2 (growth hormone releasing peptide 2) is used as a growth hormone secretagogue in research settings. It stimulates GH release through the ghrelin receptor (GHSR-1a), making it a tool for studying GH-axis physiology, body composition, appetite regulation, and sleep architecture. It is one of the most potent synthetic GH secretagogues available for research.

Is GHRP-2 better than ipamorelin?

“Better” depends on the research context. GHRP-2 produces a stronger GH response but with more off-target effects (appetite stimulation, cortisol, prolactin). Ipamorelin is more selective with a cleaner hormonal profile. GHRP-2 may suit contexts where maximal GH output matters; ipamorelin suits contexts where selectivity is prioritised. See GHRP-2 vs Ipamorelin for the full comparison.

What are the main GHRP-2 side effects?

The most common GHRP-2 side effects are increased appetite (ghrelin-pathway mediated), mild transient cortisol elevation, mild prolactin elevation, water retention, and injection site reactions. The appetite increase is the most consistently reported effect and distinguishes GHRP-2 from more selective secretagogues like ipamorelin.

How long does GHRP-2 take to work?

GH release begins within minutes of GHRP-2 administration, peaking at 15–30 minutes. The GHRP-2 half-life is approximately 15–25 minutes. However, body-composition changes require weeks to months of consistent use — GHRP-2 before and after assessments should span at least 8–12 weeks for meaningful endpoints.

What is the difference between GHRP-2 and GHRP-6?

Both are GHSR agonists, but GHRP-6 produces stronger appetite stimulation, greater cortisol and prolactin elevation, and a slightly different GH release profile. GHRP-2 is generally considered more potent for GH release with somewhat fewer off-target effects, placing it in the middle of the selectivity spectrum between GHRP-6 and ipamorelin. For the full breakdown, see GHRP-2 vs GHRP-6.

Is GHRP-2 FDA approved?

No. GHRP-2 has never received FDA approval. It has been used in clinical research settings and approved in Japan as a diagnostic agent (pralmorelin), but it does not have regulatory approval for therapeutic use in the US or UK. For FDA-approved GH-axis compounds, see tesamorelin.

References

1. Bowers CY, et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984. PMID: 6432397
2. Arvat E, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab. 2001. PMID: 11158029
3. Ionescu M, Bhatt DL. GHRP-2 as a GH secretagogue: clinical applications and pharmacology. Growth Horm IGF Res. 2005. PMID: 15936959
4. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008. PMID: 18981487

If your query is what is tesamorelin, the practical answer is: tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that is the only GHRH-pathway peptide with FDA approval (marketed as Egrifta® and Egrifta SV®). It was approved specifically for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.[1][2]

What distinguishes tesamorelin peptide from other GH-axis compounds is the depth of its clinical evidence base. Unlike most research peptides discussed on this site, tesamorelin has been evaluated in multiple randomised, double-blind, placebo-controlled trials — including studies published in JAMA and The Lancet HIV.[3][4] This clinical pedigree makes it the gold-standard reference point for the entire GHRH analog class.

Tesamorelin works by stimulating the anterior pituitary to release growth hormone in a pulsatile pattern, which then drives hepatic IGF-1 production. The downstream effects include visceral fat reduction, improved body composition, favourable metabolic marker changes, and emerging evidence for hepatoprotective and cognitive benefits.[3][4][5]

For context across the GH-axis peptide class, this page pairs naturally with CJC-1295 (a longer-acting GHRH analog without FDA approval), Sermorelin (a shorter-acting GHRH analog), and Ipamorelin (a GH secretagogue that works via the ghrelin receptor rather than GHRH).

Compound Profile

What Does Tesamorelin Actually Do?

Tesamorelin stimulates the anterior pituitary to release growth hormone, which then drives IGF-1 production and downstream metabolic effects. Unlike exogenous GH administration, tesamorelin preserves pulsatile GH secretion patterns and maintains hypothalamic-pituitary feedback regulation.[1][6]

Key findings from clinical trials:

• Visceral fat reduction: the landmark Stanley et al. (2014) JAMA trial demonstrated significant reductions in both visceral adipose tissue and liver fat in HIV-infected patients with abdominal fat accumulation.[3]
• Liver fat reduction (NAFLD): Stanley et al. (2019) in The Lancet HIV showed tesamorelin significantly reduced hepatic fat fraction and prevented NAFLD progression, with improved liver fibrosis markers.[4]
• Body composition improvement: the 2026 Badran et al. meta-analysis pooling multiple RCTs confirmed significant reductions in visceral adipose tissue, trunk fat, and waist circumference, with concurrent improvements in lean body mass.[7]
• Metabolic improvements: improved triglyceride levels, reduced inflammatory markers, and favourable changes in adipose tissue quality documented across multiple trials.[8][9]
• Cognitive function: Baker et al. (2012) demonstrated that GHRH administration (using a tesamorelin analog protocol) improved cognitive function in both healthy older adults and adults with mild cognitive impairment — a finding that broadens the potential application beyond body composition.[5]

How Tesamorelin Works

Tesamorelin is a modified form of human GHRH(1-44)-NH₂ with a trans-3-hexenoic acid group attached to the tyrosine at position 1. This modification enhances stability and receptor binding while maintaining full biological activity at the GHRH receptor.[1][2]

The mechanism operates through a well-characterised pathway:

• GHRH receptor activation: tesamorelin binds the GHRH receptor on somatotroph cells in the anterior pituitary, triggering GH synthesis and pulsatile release.[1][6]
• Pulsatile GH secretion: Stanley et al. (2011) specifically demonstrated that tesamorelin augments endogenous GH pulsatility — increasing both pulse amplitude and mean GH levels — while preserving the body’s natural secretory rhythm. This is pharmacologically important because pulsatile GH is more effective than continuous GH exposure for downstream metabolic effects.[6]
• IGF-1 cascade: elevated GH stimulates hepatic IGF-1 production, which mediates effects on body composition, tissue repair, and metabolic regulation.[3][7]
• Visceral adipose targeting: the preferential reduction in visceral (not subcutaneous) fat suggests pathway-specific lipolytic signalling, likely mediated through GH’s known effects on visceral adipocyte lipolysis and lipid oxidation.[3][8]
• Hepatoprotective effects: Fourman et al. (2020) used transcriptomic analysis to show that tesamorelin modulates hepatic gene expression in ways that reduce lipogenesis and inflammation, providing mechanistic insight into the NAFLD benefits.[10]

Fat Loss and Body Recomp Context

Fat loss and body recomposition is tesamorelin’s strongest evidence domain. The clinical trial data is more robust here than for any other peptide on this site.

The evidence hierarchy:

• JAMA RCT (2014): Stanley et al. demonstrated significant reductions in visceral adipose tissue (VAT) and liver fat over 12 months in a double-blind, placebo-controlled trial. The visceral fat reduction was maintained throughout the treatment period.[3]
• 2026 Meta-analysis: Badran et al. pooled data from multiple randomised controlled trials and confirmed consistent reductions in trunk fat, VAT, and waist circumference, with concurrent increases in lean body mass. The effect sizes were statistically and clinically significant.[7]
• Fat quality improvements: Lake et al. (2021) showed tesamorelin improves adipose tissue quality independent of quantity changes — reducing adipose tissue inflammation and improving metabolic function even before visible fat loss occurs.[9]
• Muscle composition: Adrian et al. (2019) demonstrated tesamorelin decreases intermuscular fat and increases muscle area in adults with HIV, suggesting body recomposition effects beyond simple fat reduction.[11]

The key distinction: tesamorelin’s fat loss evidence is strongest for visceral fat specifically. Subcutaneous fat reduction is less pronounced. This makes it particularly relevant for metabolic health contexts where visceral adiposity drives disease risk.

Metabolic Health and Insulin Sensitivity Context

Metabolic health and insulin sensitivity is a critical evaluation axis for tesamorelin, especially given GH’s known insulin-antagonistic effects.

• Insulin sensitivity in healthy men: Stanley et al. (2011) demonstrated that tesamorelin does not worsen insulin sensitivity in healthy subjects during GH pulsatility augmentation, an important safety signal for a GH-axis compound.[6]
• Type 2 diabetes safety: Clemmons et al. (2017) specifically evaluated tesamorelin in patients with type 2 diabetes and found acceptable metabolic safety — HbA1c did not significantly change despite GH-axis stimulation. This directly addresses the concern about GH-mediated glucose dysregulation.[12]
• Metabolic marker improvements: reductions in triglycerides, improved adipokine profiles, and reduced inflammatory markers documented across multiple trials suggest net metabolic benefit despite theoretical GH-insulin interactions.[7][8]
• Visceral fat as metabolic driver: because visceral adipose tissue is a primary driver of insulin resistance and metabolic syndrome, tesamorelin’s preferential VAT reduction may improve metabolic health through adipose reduction independent of direct insulin effects.[3][8]

The practical interpretation: tesamorelin appears to have acceptable metabolic safety even in diabetic populations, and the visceral fat reduction likely produces net metabolic benefit. Glucose monitoring remains appropriate with any GH-axis intervention.[6][12]

NAFLD and Liver Health Context

Non-alcoholic fatty liver disease (NAFLD) reduction is one of tesamorelin’s most compelling emerging applications, with high-quality trial data from The Lancet HIV.

• Lancet HIV RCT (2019): Stanley et al. conducted a randomised, double-blind, multicentre trial showing tesamorelin significantly reduced hepatic fat fraction and prevented NAFLD progression over 12 months. Among participants with NAFLD at baseline, tesamorelin resolved NAFLD in a significant proportion.[4]
• Liver enzyme improvements: Fourman et al. (2017) demonstrated that visceral fat reduction with tesamorelin is associated with improved liver enzymes (ALT, AST), linking the body composition changes to hepatic health markers.[8]
• Hepatic transcriptomic changes: Fourman et al. (2020) used liver biopsy transcriptomics to show tesamorelin downregulates hepatic lipogenesis and inflammatory gene expression, providing mechanistic evidence for liver fat reduction beyond simple GH elevation.[10]

This NAFLD data is particularly significant because no other research peptide on this site has liver-specific clinical trial evidence of this quality. While the trials were conducted in HIV-associated NAFLD, the mechanistic pathways are relevant to general NAFLD, and broader population studies are anticipated.

Cognitive Function Context

Cognitive enhancement is an emerging and genuinely interesting application for GHRH analogs including tesamorelin.

Baker et al. (2012) published in Archives of Neurology a study demonstrating that GHRH administration improved cognitive function in both healthy older adults and adults with mild cognitive impairment (MCI). The improvements were observed across multiple cognitive domains including executive function, verbal memory, and visuospatial processing.[5]

The rationale: GH and IGF-1 are known to have neurotrophic effects, supporting neuronal survival, synaptic plasticity, and cerebral blood flow. Age-related GH decline may contribute to cognitive decline through reduced IGF-1-mediated neuroprotection. GHRH-pathway stimulation via tesamorelin could potentially address this mechanism.[5]

Important caveat: this is a single study using a GHRH protocol, not a dedicated tesamorelin cognitive trial. The finding is promising and mechanistically grounded, but replication in larger populations is needed before cognitive enhancement can be considered a validated tesamorelin application.

Tesamorelin Benefits

Tesamorelin benefits are best understood through the clinical evidence hierarchy — stronger here than for any other GHRH analog:

• Visceral fat reduction: the most robustly demonstrated benefit, confirmed across multiple RCTs and a 2026 meta-analysis. Clinically and statistically significant reductions in VAT, trunk fat, and waist circumference.[3][7]
• NAFLD improvement: significant hepatic fat reduction and NAFLD resolution demonstrated in a Lancet HIV multicentre RCT.[4]
• Body recomposition: concurrent lean mass increases alongside fat reduction, with improved muscle-to-fat ratios documented in multiple studies.[7][11]
• Metabolic marker improvements: reduced triglycerides, improved inflammatory markers, better adipose tissue quality.[8][9]
• Preserved pulsatile GH secretion: augments natural GH pulsatility rather than replacing it, maintaining physiological regulation.[6]
• Cognitive function improvement: early evidence for benefits in executive function and verbal memory in older adults.[5]
• FDA-approved safety profile: tesamorelin is the only GHRH analog with an established regulatory safety and efficacy record.[1][2]

The practical takeaway: tesamorelin has the strongest evidence base of any GHRH analog, with clinical trial quality that far exceeds the typical research peptide. Benefits of tesamorelin are most clearly demonstrated for visceral fat reduction and liver health, with emerging signals for cognition and broader metabolic improvement.[7]

Tesamorelin Side Effects

For tesamorelin side effects intent, the safety profile benefits from extensive clinical trial data and FDA post-marketing surveillance:

• Injection site reactions: the most commonly reported adverse event across all trials — redness, swelling, itching, or pain at the injection site. Generally mild and self-limiting.[1][2]
• Arthralgia (joint pain): reported in clinical trials, likely related to GH/IGF-1 elevation. Usually mild to moderate.[2][7]
• Peripheral oedema: fluid retention effects consistent with GH-axis stimulation. Typically transient and manageable.[2]
• Paraesthesia: tingling or numbness, particularly in extremities. A known GH-related effect.[2]
• Glucose metabolism effects: GH has known insulin-antagonistic properties. However, Clemmons et al. (2017) found tesamorelin did not significantly worsen glycaemic control in type 2 diabetic patients.[12] Glucose monitoring remains appropriate.
• Hypersensitivity reactions: rare but documented in prescribing information. Contraindicated in patients with known hypersensitivity to tesamorelin or mannitol.[2]

The 2026 Badran meta-analysis confirmed that tesamorelin’s overall safety profile across pooled RCTs is acceptable, with adverse events predominantly mild and injection-site-related.[7] The Russo et al. (2024) study in patients on integrase inhibitors further confirmed tolerability in contemporary antiretroviral therapy contexts.[13]

Half-Life

Tesamorelin has a plasma half-life of approximately 26 minutes after subcutaneous injection. Despite this relatively short half-life, the downstream GH and IGF-1 effects persist substantially longer due to the cascade nature of the signalling pathway.[1][2]

For comparison within the GHRH analog class:

• Native GHRH: under 10 minutes (rapidly degraded by DPP-IV)
• Sermorelin: approximately 10-20 minutes
• Tesamorelin: approximately 26 minutes (trans-3-hexenoic acid modification provides moderate stability enhancement)
• CJC-1295 without DAC: approximately 30 minutes
• CJC-1295 with DAC: approximately 5-8 days (albumin binding)

Practical takeaway: tesamorelin’s half-life is short, but the GH/IGF-1 response it triggers extends well beyond the peptide’s own plasma persistence. Clinical dosing is typically once daily, and the cumulative metabolic effects build over weeks to months of consistent use.[1][3]

Is Tesamorelin FDA Approved?

Yes. Tesamorelin (marketed as Egrifta® and Egrifta SV®) received FDA approval in 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It remains the only GHRH analog with FDA approval for any indication.[1][2]

This regulatory status is significant because it means tesamorelin has undergone the full FDA review process including Phase III clinical trials, manufacturing quality controls, and post-marketing safety surveillance. This level of regulatory scrutiny exceeds that of any other GHRH analog or GH secretagogue peptide currently available.[2]

Important distinction: FDA approval is specifically for HIV-associated lipodystrophy. Use in other populations (general fat loss, anti-aging, cognitive enhancement, Egrifta bodybuilding contexts) would be off-label. The clinical evidence supports broader applications, but the regulatory indication is specific.[1][2]

Limits of Current Evidence

• Clinical trial evidence is strong but population-specific. Most RCTs were conducted in HIV-associated lipodystrophy populations. Whether effect sizes translate identically to non-HIV populations is plausible but not yet confirmed by large-scale trials.[3][4][7]
• NAFLD evidence is promising but limited to HIV-associated NAFLD. The mechanistic pathways are relevant to general NAFLD, but dedicated trials in non-HIV NAFLD populations are needed.[4][10]
• Cognitive evidence is early-stage. The Baker et al. study is a single trial. Replication in larger populations with tesamorelin specifically is needed.[5]
• Long-term effects beyond 12-18 months are less characterised. Most trials run 6-12 months. Post-marketing surveillance provides safety data but limited long-term efficacy tracking.[7]
• Visceral fat regain after discontinuation. Some evidence suggests fat reaccumulation after stopping tesamorelin, raising questions about duration of benefit.[3]
• Cost and access. As an FDA-approved branded product, tesamorelin (Egrifta) is significantly more expensive than other GHRH analogs, which affects practical accessibility outside clinical settings.

Decision rule: tesamorelin has the highest evidence quality in the GHRH analog class. Confidence is strongest for visceral fat reduction in the studied populations. Confidence decreases for non-HIV populations, cognitive claims, and long-term outcome durability. Even so, the overall evidence base far exceeds that of comparable peptides like CJC-1295 or Sermorelin.

Verdict

Tesamorelin occupies a unique position in the peptide landscape: it is the only GHRH analog with FDA approval, the strongest clinical trial evidence base, and the most robust body composition data. For Fat Loss & Recomp and Metabolic Health goals specifically, tesamorelin is the benchmark against which other GH-axis peptides should be measured.[3][7]

The compound’s profile extends beyond fat loss into NAFLD reduction, metabolic marker improvement, body recomposition, and emerging cognitive benefits. The breadth and quality of evidence is unusual for a peptide compound and provides a higher confidence foundation for interpretation than most alternatives.

For navigation, map this profile to Fat Loss & Recomp, Body Recomp, and Metabolic Health / Insulin Sensitivity. Pressure-test against Tesamorelin vs CJC-1295 and Tesamorelin vs Sermorelin, and cross-reference with CJC-1295, Sermorelin, and Ipamorelin for the full GH-axis class comparison.

FAQ

What is tesamorelin?

Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates pulsatile GH secretion from the anterior pituitary. Marketed as Egrifta®, it was approved in 2010 for reduction of excess abdominal fat in HIV-associated lipodystrophy. It has the strongest clinical evidence base of any GHRH analog.[1][2]

What does tesamorelin peptide do?

Tesamorelin activates the GHRH receptor on pituitary somatotroph cells, stimulating growth hormone release while preserving natural pulsatile secretion patterns. Clinical trials demonstrate visceral fat reduction, liver fat reduction, body recomposition, metabolic marker improvements, and emerging cognitive benefits.[3][4][5]

Is tesamorelin FDA approved?

Yes. Tesamorelin received FDA approval in 2010 for HIV-associated lipodystrophy (excess abdominal fat). It is marketed as Egrifta® and Egrifta SV® and is the only GHRH analog with FDA approval. Use for general fat loss, anti-aging, or cognitive enhancement would be off-label.[1][2]

Is tesamorelin a steroid?

No. Tesamorelin is a peptide hormone analog, not an anabolic steroid. It works by stimulating the body’s own growth hormone release through the GHRH receptor pathway. It does not directly affect testosterone or other steroid hormone pathways.[1]

What are tesamorelin benefits?

The most robustly demonstrated benefits include visceral fat reduction (confirmed by meta-analysis), NAFLD improvement (Lancet HIV RCT), body recomposition (increased lean mass alongside fat reduction), metabolic marker improvements, and cognitive function enhancement in older adults. The evidence quality exceeds that of other GHRH analogs.[3][4][5][7]

What are tesamorelin side effects?

Common side effects include injection site reactions (most frequent), arthralgia, peripheral oedema, and paraesthesia. The safety profile across pooled clinical trials is well-characterised, with adverse events predominantly mild. Glucose monitoring is appropriate with any GH-axis compound, though tesamorelin showed acceptable glycaemic safety even in type 2 diabetic patients.[2][7][12]

Tesamorelin dose and tesamorelin dosage: why not listed here?

This page is informational only and does not provide dosing protocols. The FDA-approved prescribing information for Egrifta provides the clinical dosing framework. This profile focuses on mechanism context, evidence quality, and risk-aware interpretation.

How long does it take for tesamorelin to work?

Clinical trials typically show measurable visceral fat reduction within 12-26 weeks, with effects continuing to build over 12 months of consistent use. GH and IGF-1 elevation occurs within days, but the downstream body composition and metabolic effects are gradual and cumulative.[3][7]

Does tesamorelin work for general fat loss?

Clinical evidence demonstrates tesamorelin preferentially reduces visceral (abdominal) fat rather than subcutaneous fat. This is important: if the goal is visible subcutaneous fat reduction, tesamorelin’s profile may not match expectations. Its strength is metabolically significant visceral fat reduction and associated health improvements.[3][7]

Is tesamorelin safe?

Tesamorelin has undergone full FDA regulatory review including Phase III trials and post-marketing surveillance. The 2026 meta-analysis confirmed acceptable safety across pooled RCTs. Side effects are predominantly mild injection-site reactions. It was well tolerated even in metabolically sensitive populations including type 2 diabetics.[7][12][13]

Tesamorelin for muscle growth: does it work?

Tesamorelin has demonstrated increases in lean body mass alongside fat reduction in clinical trials. Adrian et al. (2019) specifically showed decreased intermuscular fat and increased muscle area. However, it is best framed as a body recomposition and recovery support compound rather than a primary muscle-building agent. Effects are mediated through GH/IGF-1 pathways.[7][11]

Is tesamorelin worth it?

For visceral fat reduction and metabolic health improvement, tesamorelin has the strongest evidence of any GHRH analog — including FDA approval and multiple RCTs. The main practical consideration is cost: as a branded pharmaceutical, Egrifta is significantly more expensive than other peptide options. Whether that premium is “worth it” depends on the specific context, goals, and whether the stronger evidence base justifies the cost differential versus alternatives like CJC-1295 or Sermorelin.

References

1. Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071-1091. PMID: 21668043.
2. Falutz J. Tesamorelin: a novel therapeutic option for HIV/HAART-associated increased visceral adipose tissue. Drugs Today (Barc). 2011;47(10):751-761. PMID: 21695284.
3. Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. PMID: 25038357.
4. Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PMID: 31611038.
5. Baker LD, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol. 2012;69(11):1420-1429. PMID: 22869065.
6. Stanley TL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. PMID: 20943777.
7. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a systematic review and meta-analysis. Obes Res Clin Pract. 2026;20(1):1-12. PMID: 41545261.
8. Fourman LT, et al. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS. 2017;31(16):2253-2260. PMID: 28832410.
9. Lake JE, et al. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS. 2021;35(6):967-972. PMID: 33756511.
10. Fourman LT, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020;5(16):e140134. PMID: 32701508.
11. Adrian S, et al. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019;8(3):154-159. PMID: 31237318.
12. Clemmons DR, et al. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: a randomized, placebo-controlled trial. PLoS One. 2017;12(6):e0179538. PMID: 28617838.
13. Russo SC, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(11):1622-1629. PMID: 38905488.

If your query is what is sermorelin, the practical answer is: sermorelin (also known as sermorelin acetate or GRF 1-29) is the first 29 amino acids of human growth hormone-releasing hormone (GHRH). It is a historically significant compound — the first GHRH analog to receive FDA approval (as Geref® for paediatric GH deficiency diagnosis and treatment), giving it the longest clinical track record of any GHRH-pathway peptide.[1][2][3]

Sermorelin peptide stimulates the anterior pituitary to release growth hormone in a pulsatile pattern that preserves the body’s natural GH secretory rhythm. Unlike exogenous GH, sermorelin works through the GHRH receptor rather than bypassing pituitary regulation, which is considered physiologically advantageous for maintaining feedback integrity.[1][4]

Khorram et al. (1997) conducted one of the most important sermorelin aging studies, demonstrating that long-term administration of GRF(1-29)-NH₂ in age-advanced men and women produced sustained increases in IGF-1, improvements in lean body mass, and enhanced immune function markers — without the adverse effects associated with exogenous GH.[1][5]

For context across the GH-axis peptide class, this page pairs naturally with CJC-1295 (a modified, longer-acting GHRH analog), Tesamorelin (an FDA-approved GHRH analog with stronger body composition data), and Ipamorelin (a GH secretagogue that works via the ghrelin receptor rather than GHRH).

Compound Profile

What Does Sermorelin Actually Do?

Sermorelin stimulates the anterior pituitary to release growth hormone in pulses that mirror the body’s natural secretory rhythm. The practical result is elevated GH and IGF-1 levels achieved through physiological pathways rather than pharmacological override.[1][2][4]

Key findings from human studies:

• Long-term GH axis restoration in aging: Khorram et al. (1997) administered GRF(1-29)-NH₂ nightly for 16 weeks to men and women aged 55-71. Results: significant increases in 24-hour GH secretion, elevated IGF-1 levels, increased lean body mass, and reduced body fat — with improvements sustained throughout the treatment period.[1]
• Immune function enhancement: in a companion study, Khorram et al. (1997) demonstrated that the same GRF(1-29) protocol increased natural killer cell number, improved lymphocyte proliferation, and enhanced immune responsiveness in elderly subjects.[5]
• Paediatric growth stimulation: Brain et al. (1990) showed that continuous subcutaneous GHRH(1-29)-NH₂ promoted growth over 12 months in short, slowly growing children — the clinical basis for the original FDA approval.[3]
• Sleep-GH relationship: Jessup et al. (2004) demonstrated that endogenous GHRH receptor activation is specifically linked to nocturnal GH secretion, supporting the mechanistic basis for sermorelin’s reported sleep quality effects.[6]
• Body composition in hypogonadal men: Sinha et al. (2020) reviewed GH secretagogues as body composition management tools, noting GHRH analogs like sermorelin as adjuncts for lean mass maintenance and fat reduction in clinical contexts.[7]

How Sermorelin Works

Sermorelin is the native human GHRH(1-29) sequence — the biologically active fragment of the full 44-amino-acid GHRH molecule. Research established that the first 29 amino acids retain full biological activity at the GHRH receptor, making the remaining 15 residues dispensable.[2][4]

The mechanism operates through a well-characterised pathway:

• GHRH receptor binding: sermorelin binds the GHRH receptor on somatotroph cells in the anterior pituitary, triggering intracellular cAMP signalling that stimulates both GH synthesis and release.[2][4]
• Pulsatile secretion preservation: unlike exogenous GH, sermorelin works through the hypothalamic-pituitary axis, meaning somatostatin-mediated feedback remains intact. GH is released in natural pulses rather than continuous elevation.[1][4]
• IGF-1 cascade: elevated GH drives hepatic IGF-1 production, which mediates downstream effects on body composition, tissue repair, immune function, and metabolic regulation.[1][5]
• Nocturnal GH amplification: sermorelin administration (typically evening/bedtime) amplifies the largest natural GH pulse, which occurs during slow-wave sleep. Jessup et al. (2004) confirmed the specific link between GHRH receptor activity and nocturnal GH secretion.[6]

The key pharmacological limitation: sermorelin uses the unmodified native GHRH(1-29) sequence, which is rapidly degraded by DPP-IV enzymes. This gives it a very short half-life (~10-20 minutes), requiring precise timing and more frequent administration compared to modified GHRH analogs like CJC-1295 or Tesamorelin.[2][8]

Recovery and Sleep Context

Recovery and sleep is one of sermorelin’s most practically relevant domains. The relationship between GHRH, nocturnal GH secretion, and sleep quality is well-established in the neuroendocrine literature.[6]

The mechanistic basis:

• Sleep-GH coupling: the majority of daily GH secretion occurs during slow-wave (deep) sleep. GHRH receptor activation specifically amplifies this nocturnal pulse. Jessup et al. (2004) demonstrated that blocking endogenous GHRH receptors reduced nocturnal GH secretion without altering sleep architecture — confirming that GHRH drives the GH pulse rather than sleep itself driving GH release.[6]
• Recovery quality: elevated nocturnal GH supports tissue repair, protein synthesis, and glycogen replenishment during sleep. In practical contexts, sermorelin users most commonly report improved recovery feel upon waking and better training readiness.
• Evening dosing rationale: sermorelin’s short half-life and the nocturnal GH pulse timing create a natural dosing window — evening administration amplifies the existing sleep-linked GH surge rather than creating an artificial pattern.

Important caveat: sermorelin may improve the recovery value of sleep (via GH amplification) without necessarily changing sleep duration or architecture. The benefit is more accurately framed as enhanced physiological recovery during sleep rather than a sleep aid.

Muscle Growth and Performance Context

Muscle growth and performance support relevance for sermorelin operates through the GH/IGF-1 axis. Elevated IGF-1 supports protein synthesis, nitrogen retention, and recovery from training-induced tissue damage — but these effects are indirect and baseline-dependent.[1][7]

• Lean body mass increases: Khorram et al. (1997) documented significant lean body mass increases in elderly subjects over 16 weeks of GRF(1-29) administration, alongside reductions in body fat percentage.[1]
• Body composition management: Sinha et al. (2020) positioned GH secretagogues including GHRH analogs as tools for lean mass maintenance and fat reduction, particularly in hypogonadal or aging contexts where GH decline compounds muscle loss.[7]
• Recovery-driven performance: the primary performance mechanism is through improved recovery quality rather than direct anabolic effects. Better recovery between training sessions enables higher training consistency and volume tolerance over time.

Practical interpretation: sermorelin is a recovery and body-composition support compound rather than a direct muscle-building agent. Value is typically most visible in contexts where training fundamentals are stable and outcomes are tracked across multi-week blocks. For dedicated muscle growth goals, sermorelin’s contribution is primarily through recovery optimisation and hormonal environment support.

Longevity and Healthy Aging Context

Longevity and healthy aging is arguably sermorelin’s strongest theoretical domain. The age-related decline in GH secretion (somatopause) is one of the most well-documented endocrine changes of aging, and GHRH analogs represent a more physiological intervention approach than exogenous GH.[1][4][9]

• Somatopause intervention: GH secretion declines approximately 14% per decade after age 30, with corresponding IGF-1 reductions. Merriam et al. (2003) argued that GHRH analogs and GH secretagogues offer a safer, more physiological approach to somatopause than exogenous GH because they preserve pulsatile secretion and hypothalamic-pituitary feedback.[4]
• Multi-system aging benefits: the Khorram studies documented improvements across multiple aging-relevant domains — lean mass, body fat, immune function, and IGF-1 levels — in elderly subjects treated with GRF(1-29).[1][5]
• Immune senescence: Khorram et al. (1997) specifically showed enhanced NK cell activity and lymphocyte function in elderly subjects — addressing immune decline as a component of the aging process.[5]
• Safety advantage: Sattler (2013) noted that GHRH analogs maintain the body’s regulatory feedback mechanisms, reducing the risks associated with supraphysiological GH levels (fluid retention, insulin resistance, joint pain) that can occur with exogenous GH.[9]

The practical positioning for longevity: sermorelin’s pulsatility preservation and physiological approach make it conceptually well-suited for long-term GH-axis support. The trade-off is its short half-life requiring daily dosing, versus newer analogs like CJC-1295 that provide more sustained elevation. Whether sharp, natural-pattern GH pulses (sermorelin) or sustained elevation (CJC-1295) is preferable for longevity remains an open question.[4][8]

Hormonal Support Context

Testosterone and hormonal support relevance for sermorelin is indirect. Sermorelin acts on the GH axis specifically, not the hypothalamic-pituitary-gonadal (HPG) axis that governs testosterone production.[1][4]

However, GH and testosterone systems interact bidirectionally. Sinha et al. (2020) specifically positioned GH secretagogues as adjuncts in hypogonadal management, noting that adequate GH signalling supports the broader endocrine environment. The recovery, sleep, and body composition improvements mediated by GH-axis optimisation may indirectly support hormonal balance.[7][9]

The honest framing: sermorelin is a GH-axis compound with possible indirect hormonal environment benefits. It is not a testosterone replacement or direct androgenic agent. For dedicated hormonal support, evaluate it as part of a broader strategy rather than a standalone intervention.

Sermorelin Benefits

Sermorelin benefits are best understood through the evidence hierarchy:

• Physiological GH axis restoration: stimulates natural pulsatile GH secretion via the GHRH receptor, maintaining hypothalamic-pituitary feedback — the most natural approach to GH-axis support available.[1][2][4]
• Lean body mass improvement: significant increases documented in elderly subjects over 16 weeks, alongside body fat reductions.[1]
• Immune function enhancement: improved NK cell activity and lymphocyte function in aging populations, addressing immune senescence.[5]
• Recovery and sleep support: amplification of nocturnal GH pulses supports tissue repair and recovery quality during sleep.[6]
• Longest clinical safety history: as the first FDA-approved GHRH analog (Geref®, 1997), sermorelin has the longest clinical track record of any compound in its class.[2][3]
• Well-tolerated safety profile: Sigalos & Pastuszak (2018) reviewed GH secretagogues as a class and concluded they have acceptable safety profiles, with sermorelin’s established history providing additional confidence.[8]
• Somatopause mitigation: addresses age-related GH decline through physiological mechanisms rather than pharmacological replacement.[1][4][9]

Evidence-weighted read: multi-system aging benefits (lean mass, immune function, IGF-1) are supported by controlled human studies. Sleep and recovery benefits are mechanistically grounded and practically reported but less formally studied. Benefits of sermorelin are strongest when fundamentals are stable and outcomes are tracked across weeks.[1][5]

Sermorelin Side Effects

For sermorelin side effects intent, the safety profile benefits from sermorelin’s extensive clinical history:

• Injection site reactions: redness, swelling, or discomfort at injection sites. The most commonly reported adverse effect across clinical use.[2][8]
• Flushing: transient warmth or facial flushing after injection, typically resolving within minutes.[2]
• Headache: reported in some subjects, usually mild and transient.[2]
• Dizziness: occasionally reported, generally mild.[2]
• Difficulty swallowing or taste changes: uncommon but documented in prescribing information.[2]
• Antibody formation: long-term use can trigger anti-GHRH antibodies that may reduce efficacy over time. This is a known consideration with peptide therapies and may require periodic evaluation.[2][3]

The Khorram aging studies reported the GRF(1-29) protocol was well tolerated over 16 weeks in elderly subjects, with no serious adverse events.[1][5] Sigalos & Pastuszak’s 2018 safety review confirmed that GH secretagogues as a class have acceptable safety profiles, while noting the need for longer-term surveillance in general use.[8]

Compared to exogenous GH, sermorelin’s side effect profile is generally milder because it works through physiological pathways: fluid retention, joint pain, and insulin resistance — common with exogenous GH — are less frequent with GHRH-pathway stimulation that preserves feedback regulation.[4][8][9]

Half-Life

Sermorelin has a plasma half-life of approximately 10-20 minutes after subcutaneous injection. This is the shortest half-life of any commonly discussed GHRH analog, and it is sermorelin’s primary pharmacological limitation.[2][8]

For comparison within the GHRH analog class:

• Native GHRH (1-44): under 10 minutes (rapidly degraded by DPP-IV)
• Sermorelin (GRF 1-29): approximately 10-20 minutes (slightly more stable than full-length GHRH)
• Tesamorelin: approximately 26 minutes (trans-3-hexenoic acid modification)
• CJC-1295 without DAC: approximately 30 minutes (DPP-IV-resistant modifications)
• CJC-1295 with DAC: approximately 5-8 days (albumin binding)

Practical implications: sermorelin’s short half-life means timing is critical. Evening administration aligns with the natural nocturnal GH surge. The rapid clearance produces a sharp, defined GH pulse followed by return to baseline — which some view as more physiologically natural than sustained elevation, though it requires more precise dosing discipline.[2][6]

Sermorelin for Weight Loss and Fat Loss Context

For sermorelin for weight loss and sermorelin for fat loss intent: body composition improvement through GH-axis stimulation is a frequently discussed application, with supporting evidence from the Khorram aging studies.

• Fat reduction documented: Khorram et al. (1997) showed significant reductions in body fat percentage in elderly subjects over 16 weeks of GRF(1-29) administration.[1]
• Mechanism: GH promotes lipolysis (fat breakdown) primarily through mobilisation of fatty acids from adipose tissue. Elevated GH/IGF-1 from sermorelin stimulation can shift substrate utilisation toward fat oxidation.[1][7]
• Realistic expectations: sermorelin’s fat loss effect is modest compared to dedicated weight loss compounds like semaglutide or tirzepatide. The primary mechanism is gradual body composition improvement (more lean mass, less fat) rather than rapid weight reduction.

The honest assessment: sermorelin can contribute to fat loss as part of a comprehensive approach including training and nutrition, but it is not a standalone weight loss solution. Its strength is body recomposition (improving the ratio) rather than dramatic scale weight reduction. For dedicated fat loss goals, compare against compounds with stronger weight loss evidence.

Limits of Current Evidence

• Key human studies are from the 1990s. The Khorram aging studies remain the most relevant sermorelin-specific human data. Newer research has largely focused on modified analogs (CJC-1295, tesamorelin) rather than native GRF(1-29).[1][5]
• Small sample sizes in aging studies. The Khorram studies used relatively small cohorts. While results are consistent and biologically plausible, larger confirmatory trials would strengthen confidence.[1][5]
• Short half-life is a practical limitation. The 10-20 minute half-life makes sermorelin the least pharmacokinetically convenient option in its class. Modern alternatives offer longer duration of action with comparable or superior efficacy.[2][8]
• FDA approval withdrawn. Geref® was withdrawn from the US market in 2008 for commercial (not safety) reasons, which means sermorelin currently lacks active FDA marketing authorisation.[2]
• Antibody formation. Long-term use may trigger anti-GHRH antibodies that reduce efficacy, a consideration for sustained use.[2][3]
• Limited head-to-head comparisons. No direct clinical trials compare sermorelin to CJC-1295 or tesamorelin in matched populations. Relative positioning is inferred from independent study results and mechanistic reasoning.

Decision rule: sermorelin has solid human evidence for GH-axis stimulation and multi-system aging benefits, but the evidence base is older and smaller than for newer GHRH analogs. Its primary advantage is the longest clinical safety history and the most physiological approach to GH-axis support. Its primary limitation is pharmacokinetic convenience.

Verdict

Sermorelin is the original GHRH analog — the compound that established the proof of concept for GH-axis stimulation through the pituitary pathway. Its native GRF(1-29) sequence represents the most physiological approach to GH augmentation: preserving pulsatility, maintaining feedback regulation, and amplifying the body’s own GH secretory capacity.[1][2][4]

Where it fits today: sermorelin remains relevant for contexts that prioritise physiological naturalness and safety track record over pharmacokinetic convenience. The Khorram aging studies documented meaningful improvements in lean mass, body fat, IGF-1 levels, and immune function in elderly subjects — a multi-system benefit profile that aligns well with longevity and healthy aging goals.[1][5]

The practical trade-off: newer GHRH analogs like CJC-1295 and Tesamorelin offer longer half-lives, more robust clinical data (tesamorelin especially), and greater dosing convenience. Sermorelin’s value proposition is its native sequence, established safety history, and sharp physiological GH pulsatility — for those who prioritise these characteristics over convenience.

For navigation, map this profile to Longevity / Healthy Aging, Recovery & Sleep, Muscle Growth, and Hormonal Support. Pressure-test with Ipamorelin vs Sermorelin, CJC-1295 vs Sermorelin, and Tesamorelin vs Sermorelin, and cross-reference with GHRP-2 for an alternative secretagogue pathway.

FAQ

What is sermorelin?

Sermorelin (sermorelin acetate, GRF 1-29) is the first 29 amino acids of human growth hormone-releasing hormone. It was the first GHRH analog to receive FDA approval (as Geref® in 1997) and has the longest clinical track record of any GH-axis peptide. It stimulates natural, pulsatile GH secretion through the GHRH receptor.[1][2][3]

What does sermorelin peptide do?

Sermorelin activates the GHRH receptor on pituitary somatotroph cells, stimulating growth hormone synthesis and pulsatile release while preserving natural feedback regulation. Human studies demonstrate increased GH and IGF-1 levels, lean body mass improvements, fat reduction, and enhanced immune function in elderly subjects.[1][5]

What are sermorelin benefits?

Key benefits include physiological GH axis restoration, lean body mass improvement, body fat reduction, immune function enhancement, recovery and sleep support, and somatopause mitigation. Sermorelin has the longest safety history of any GHRH analog. Benefits are most visible when fundamentals (training, nutrition, sleep) are stable and tracked across weeks.[1][5][6]

What are sermorelin side effects?

Common side effects include injection site reactions, transient flushing, headache, and dizziness. The safety profile is generally milder than exogenous GH because sermorelin works through physiological pathways. Long-term use may trigger anti-GHRH antibodies. The Khorram studies reported the compound was well tolerated in elderly subjects.[1][2][8]

Sermorelin dose and sermorelin dosage: why not listed here?

This page is informational only and does not provide dosing protocols. This profile focuses on mechanism context, evidence quality, and risk-aware interpretation. Refer to primary research literature for protocol parameters.

Ipamorelin vs Sermorelin: which pathway and why compare them?

They stimulate GH through completely different receptors. Sermorelin works via the GHRH receptor; Ipamorelin works via the ghrelin receptor (GHS-R). This makes them complementary rather than competitive — they can theoretically be combined for dual-pathway stimulation. See Ipamorelin vs Sermorelin for the full comparison.[4][8]

CJC-1295 vs Sermorelin: what is the useful distinction?

Both are GHRH analogs targeting the same receptor, but CJC-1295 has modified amino acids that resist enzymatic degradation, extending its half-life from sermorelin’s ~10-20 minutes to ~30 minutes (no-DAC) or 5-8 days (with DAC). CJC-1295 offers convenience; sermorelin offers the most natural GH pulse pattern and longest safety history. See CJC-1295 vs Sermorelin.[2][8]

Does sermorelin work for weight loss?

Sermorelin can contribute to body composition improvement (reduced fat, increased lean mass) through GH-axis stimulation. Khorram et al. documented significant fat reduction in elderly subjects. However, it is not a dedicated weight loss compound — for substantial weight reduction, GLP-1 receptor agonists like semaglutide have far stronger evidence.[1]

Is sermorelin FDA approved?

Sermorelin was FDA-approved as Geref® in 1997 for paediatric GH deficiency diagnosis and treatment. The approval was withdrawn from the US market in 2008 for commercial (not safety) reasons. It currently lacks active FDA marketing authorisation but retains its historical regulatory safety record.[2][3]

How long does sermorelin take to work?

GH and IGF-1 elevation occurs within days of starting sermorelin. Body composition and recovery improvements typically become measurable over 4-8 weeks. The Khorram aging studies assessed outcomes at 16 weeks. Judge results by multi-week trends rather than day-to-day impressions.[1]

Is sermorelin safe?

Sermorelin has the longest clinical safety history of any GHRH analog, spanning decades of use. The Khorram studies reported no serious adverse events in elderly subjects over 16 weeks. Sigalos & Pastuszak’s 2018 review confirmed acceptable safety for GH secretagogues as a class. Side effects are generally milder than exogenous GH due to physiological feedback preservation.[1][5][8]

What should be tracked when evaluating sermorelin?

Recovery quality upon waking, training readiness consistency, body composition trends (ideally via DEXA or calibrated measurements), sleep quality impressions, and overall energy levels. Track across 4+ week blocks with controlled fundamentals. Single-day assessments are unreliable due to the many confounding variables that affect these outcomes independently.

References

1. Khorram O, et al. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH₂ in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. PMID: 9141536.
2. Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021;14(1):76-86. PMID: 34665524.
3. Brain CE, et al. Continuous subcutaneous GHRH(1-29)-NH₂ promotes growth over 1 year in short, slowly growing children. Clin Endocrinol (Oxf). 1990;32(3):375-386. PMID: 2140733.
4. Merriam GR, et al. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine. 2003;22(1):41-48. PMID: 14610297.
5. Khorram O, et al. Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH₂ administration on the immune system of aging men and women. J Clin Endocrinol Metab. 1997;82(11):3590-3596. PMID: 9360512.
6. Jessup SK, et al. Blockade of endogenous growth hormone-releasing hormone receptors dissociates nocturnal growth hormone secretion and slow-wave sleep. Eur J Endocrinol. 2004;151(5):561-566. PMID: 15538933.
7. Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. PMID: 32257855.
8. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28400207.
9. Sattler FR. Growth hormone in the aging male. Best Pract Res Clin Endocrinol Metab. 2013;27(4):541-555. PMID: 24054930.
10. Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026;54(1):223-229. PMID: 41476424.
11. Baker LD, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol. 2012;69(11):1420-1429. PMID: 22869065.

If your query is what is CJC-1295, the practical answer is: CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates pulsatile growth hormone (GH) secretion from the anterior pituitary. It is one of the most widely discussed CJC-1295 peptide compounds in GH-axis research contexts.[1][2]

In the landmark human study, Teichman et al. (2006) demonstrated that a single dose of CJC-1295 produced sustained 2- to 10-fold increases in GH concentration and 1.5- to 3-fold increases in IGF-1 levels, with effects persisting for up to 6 days after injection. After multiple doses, mean IGF-1 levels increased by 1.5- to 3-fold for 9 to 11 days.[1] This prolonged duration distinguishes CJC-1295 from shorter-acting GHRH analogs like Sermorelin.

Importantly, Ionescu & Bhatt (2006) confirmed that pulsatile GH secretion is preserved during continuous CJC-1295 stimulation, meaning the compound works within the body’s natural secretory rhythm rather than overriding it.[2] This pulsatility preservation is a key pharmacological advantage over exogenous GH administration.

For context across the GH-axis peptide class, this page pairs naturally with Ipamorelin (a GH secretagogue that works via the ghrelin receptor rather than GHRH), Sermorelin (a shorter-acting GHRH analog), and Tesamorelin (a GHRH analog with FDA approval for HIV-associated lipodystrophy).

Compound Profile

What Does CJC-1295 Actually Do?

CJC-1295 peptide stimulates the anterior pituitary to release growth hormone in a pulsatile pattern that mirrors natural GH secretion. The practical effect is an elevated GH/IGF-1 baseline over days rather than hours, which is why CJC-1295 is typically evaluated by multi-week trend quality rather than acute single-dose response.[1][2]

Key findings from human and preclinical data:

• Sustained GH elevation: 2- to 10-fold increases in GH concentration persisting for up to 6 days after a single injection in healthy adults.[1]
• IGF-1 amplification: 1.5- to 3-fold increases in IGF-1 levels sustained for 9 to 11 days after multiple doses, indicating cumulative signalling.[1]
• Pulsatility preservation: unlike exogenous GH, CJC-1295 maintains the body’s natural pulsatile GH secretion pattern, which is considered physiologically important for downstream signalling quality.[2]
• Serum protein profile changes: Sackmann-Sala et al. (2009) documented measurable changes in serum protein profiles in healthy subjects following CJC-1295 administration, suggesting broader systemic effects beyond isolated GH elevation.[3]
• GRF receptor activation: the parent sequence GRF(1-29) activates the GHRH receptor on the anterior pituitary with high specificity, and CJC-1295’s modifications extend this activation window.[4]

The practical interpretation framework: CJC-1295 creates a more favourable GH signalling environment over time. Whether that translates into measurable recovery, body composition, or sleep benefits depends on baseline conditions, training structure, and how consistently fundamentals are controlled.

How CJC-1295 Works

CJC-1295 is a modified version of the first 29 amino acids of growth hormone-releasing hormone (GHRH, also called GRF 1-29). The modifications serve two purposes: protecting the peptide from enzymatic degradation (DPP-IV cleavage) and, in the DAC version, enabling covalent binding to serum albumin for extended half-life.[1][4]

The mechanism operates through a well-characterised pathway:

• GHRH receptor binding: CJC-1295 binds the GHRH receptor on somatotroph cells in the anterior pituitary, triggering intracellular cAMP signalling that stimulates GH synthesis and release.[4][5]
• Pulsatile release preservation: the hypothalamic-pituitary feedback loop remains intact during CJC-1295 stimulation, meaning GH is released in pulses rather than continuous elevation. This is pharmacologically significant because pulsatile GH is more effective at driving IGF-1 production and downstream tissue effects than continuous GH exposure.[2]
• IGF-1 cascade: elevated GH stimulates hepatic IGF-1 production, which mediates many of the anabolic, recovery, and body composition effects attributed to the GH axis.[1][3]
• Somatostatin sensitivity retained: CJC-1295 does not override somatostatin (the GH-inhibiting hormone), meaning the body’s natural braking system remains functional. This contrasts with approaches that bypass pituitary regulation entirely.[2][5]

The engineering distinction matters: CJC-1295’s longevity comes from modified amino acids (to resist DPP-IV degradation) and, in the DAC formulation, a Drug Affinity Complex that binds albumin. This extends the effective half-life from minutes (native GHRH) to days.[1][4]

Muscle Growth and Body Recomp Context

Muscle growth and body recomposition relevance for CJC-1295 operates through the GH/IGF-1 axis. Elevated IGF-1 supports protein synthesis, nitrogen retention, and recovery from training-induced muscle damage — but these effects are indirect and baseline-dependent.[1][3]

The evidence context for GH-axis stimulation and body composition:

• IGF-1 and muscle protein synthesis: the 1.5- to 3-fold IGF-1 increases documented with CJC-1295 are within the range associated with improved recovery and anabolic signalling in GH-axis research.[1]
• Tesamorelin precedent: the closely related GHRH analog tesamorelin has demonstrated measurable body composition changes (reduced visceral fat) in clinical trials, providing directional evidence that GHRH-pathway stimulation can influence body composition.[8]
• Age-related GH decline: GH secretion decreases approximately 14% per decade after age 30. GHRH analogs like CJC-1295 are studied as potential interventions for this somatopause decline, particularly for body composition maintenance in aging populations.[6][7]

Practical interpretation: CJC-1295 is more accurately framed as a recovery and body-composition support compound than a direct muscle-building agent. Outcomes are typically most visible when training, nutrition, and sleep fundamentals are stable and tracked across multi-week blocks. For the Fat Loss & Recomp goal specifically, the GH-axis contribution is primarily through improved recovery quality and metabolic support rather than direct lipolysis.

Hormonal Support Context

Testosterone and hormonal support relevance for CJC-1295 is indirect. CJC-1295 acts on the GH axis specifically, not the hypothalamic-pituitary-gonadal (HPG) axis that governs testosterone production.[1][5]

However, GH and testosterone systems interact: adequate GH signalling supports overall endocrine environment quality, and the recovery and sleep improvements associated with GH-axis optimisation can indirectly support hormonal balance. Sattler (2013) reviewed the interplay between GH decline and broader hormonal changes in aging males, noting that GH-axis intervention may support overall endocrine resilience even when testosterone-specific effects are not the primary mechanism.[6]

The honest framing: CJC-1295 is a GH-axis compound with possible indirect hormonal environment benefits. It is not a testosterone replacement or direct androgenic agent.

Longevity and Healthy Aging Context

Longevity and healthy aging is where CJC-1295 intersects with the broader somatopause literature. The age-related decline in GH secretion is well-documented and associated with increased body fat, decreased lean mass, reduced bone density, and impaired recovery capacity.[6][7][9]

Key context from the aging literature:

• Somatopause: GH secretion declines approximately 14% per decade from age 30, with corresponding reductions in IGF-1. This decline is associated with sarcopenia, increased adiposity, and reduced functional capacity.[6][7]
• GHRH analog rationale: Merriam et al. (1997, 2003) argued that GHRH analogs and GH secretagogues represent a more physiological approach to addressing somatopause than exogenous GH, because they preserve pulsatile secretion patterns and hypothalamic-pituitary feedback.[7][9]
• Safety review: Sigalos & Pastuszak (2018) reviewed the safety and efficacy of GH secretagogues as a class, concluding that they offer a potentially safer alternative to exogenous GH for age-related GH decline, though noting that long-term human safety data remains limited.[5]

Interpretation for CJC-1295 specifically: the compound’s pulsatility preservation and sustained IGF-1 elevation make it one of the more pharmacologically interesting GHRH analogs for longevity-oriented research. But “anti-aging” claims should stay evidence-weighted: the rationale is strong, the mechanism is sound, but large-scale long-term human outcome data is not yet available.

Recovery and Sleep Context

Recovery and sleep relevance for CJC-1295 is biologically grounded: the majority of natural GH secretion occurs during slow-wave sleep. By amplifying GH pulsatility, CJC-1295 may enhance the recovery value of sleep without necessarily changing sleep architecture itself.[2][5]

The practical signal is usually reported as improved recovery feel upon waking, better training readiness, and fewer disrupted training blocks. These are indirect outcomes mediated through GH/IGF-1 elevation rather than direct sedative or sleep-promoting effects.

When evaluating recovery claims, the most reliable approach is tracking recovery quality across consistent sleep schedules over multiple weeks. Single-night impressions are unreliable due to the many confounding variables that affect sleep quality independently of GH axis status.

CJC-1295 Benefits

CJC-1295 benefits are best understood through the evidence hierarchy:

• Sustained GH/IGF-1 elevation: the most directly demonstrated benefit, with 2- to 10-fold GH increases and 1.5- to 3-fold IGF-1 increases documented in human subjects.[1]
• Preserved pulsatile secretion: unlike exogenous GH, CJC-1295 maintains natural GH pulse patterns, which is pharmacologically significant for downstream signalling quality.[2]
• Extended duration of action: the DAC version provides days of sustained activity from a single injection, reducing administration frequency compared to shorter-acting GHRH analogs.[1][4]
• Recovery support: improved recovery quality and training continuity reported in practical contexts, mediated through GH/IGF-1-dependent tissue repair pathways.[5][10]
• Body composition support: indirect support for lean mass maintenance and fat reduction through improved GH axis signalling, with GHRH-analog class evidence from tesamorelin trials providing directional support.[8]
• Aging-related GH decline mitigation: the somatopause literature supports GHRH analog use as a more physiological approach to age-related GH decline than exogenous GH.[6][7][9]

Evidence-weighted read: GH/IGF-1 elevation is well-documented in humans. Downstream clinical outcomes (body composition, recovery, aging) are supported by mechanism and class-level evidence but lack large-scale CJC-1295-specific outcome trials. Benefits of CJC-1295 are strongest when fundamentals are stable and outcomes are judged by trend quality over weeks.[1][5]

CJC-1295 Side Effects

For CJC-1295 side effects intent, the safety profile draws from the Teichman human study and broader GH secretagogue class data:

• Injection site reactions: redness, swelling, or irritation at injection sites. The most commonly reported adverse effect in the Teichman study.[1]
• Water retention: transient fluid retention and puffiness, consistent with elevated GH/IGF-1 activity. Usually resolves with hydration management.
• Headache: reported in some subjects during clinical evaluation.[1]
• Flushing or warmth: transient post-injection flushing reported in some users.
• Appetite changes: GH axis stimulation can influence appetite patterns, though direction and magnitude vary considerably between individuals.
• Glucose handling concerns: GH has known insulin-antagonistic effects. Sigalos & Pastuszak (2018) noted that glucose metabolism monitoring is appropriate with GH secretagogue use, particularly in metabolically sensitive populations.[5]
• Person-to-person variability: individual responses vary substantially. Attribution is difficult when multiple variables (training, nutrition, sleep) change simultaneously.

The Teichman study reported CJC-1295 was generally well tolerated, with adverse events mostly mild and injection-site-related.[1] Sigalos & Pastuszak’s 2018 review concluded that GH secretagogues as a class have acceptable safety profiles, while noting the need for longer-term surveillance.[5] Weekly trend logging is more reliable than single-day reactions when assessing side effect significance.

Half-Life

For CJC-1295 half-life queries: the half-life varies significantly depending on DAC status.

• CJC-1295 with DAC: approximately 5 to 8 days, owing to covalent albumin binding via the Drug Affinity Complex. This is the version used in the Teichman et al. study, which showed GH effects persisting for up to 6 days after a single dose.[1][4]
• CJC-1295 without DAC (Mod GRF 1-29): approximately 30 minutes. The DPP-IV-resistant amino acid modifications extend the half-life beyond native GHRH (which degrades in under 10 minutes) but without albumin binding, clearance remains relatively rapid.

For comparison: native GHRH has a half-life under 10 minutes. Sermorelin (GRF 1-29 without modifications) has a similarly short half-life. CJC-1295 with DAC represents a roughly 500-fold increase in persistence over native GHRH.[1][4]

Practical takeaway: use half-life as orientation for administration frequency planning, but judge outcomes by weekly recovery and output trends rather than strict pharmacokinetic clock assumptions.

CJC-1295 and Ipamorelin Combination Context

CJC-1295 and Ipamorelin (also searched as CJC-1295 Ipamorelin and CJC 1295 ipamorelin) is one of the most discussed peptide combinations in the GH-axis space. The rationale is pharmacologically sound: the two compounds stimulate GH release through distinct receptor pathways.

• CJC-1295: activates the GHRH receptor on pituitary somatotrophs → signals GH synthesis and release.[1][4]
• Ipamorelin: activates the ghrelin receptor (GHS-R) on somatotrophs → amplifies GH pulse amplitude without affecting other hormone axes (unlike older GH secretagogues like GHRP-6 that also influence cortisol and prolactin).[5][10]

The combination is discussed as potentially synergistic because GHRH-pathway and ghrelin-pathway stimulation are known to produce greater GH release together than either pathway alone.[5] In practical contexts, CJC-1295 ipamorelin benefits discussions typically centre on enhanced recovery quality, improved sleep-linked GH pulsatility, and more consistent training readiness.

Important caveats: no published clinical trial has specifically studied CJC-1295 + Ipamorelin in combination. The synergy rationale is extrapolated from pathway-level pharmacology and class-level GH secretagogue data. See CJC-1295 vs Ipamorelin for the full comparison breakdown.

Limits of Current Evidence

• Human pharmacokinetic and pharmacodynamic data is solid for CJC-1295 with DAC, thanks to the Teichman (2006) and Ionescu (2006) studies. GH/IGF-1 elevation in humans is well-documented.[1][2]
• Clinical outcome data is limited. No large-scale trials have evaluated CJC-1295 for specific clinical endpoints (body composition, recovery, aging). Most outcome evidence comes from class-level GHRH analog data and the tesamorelin precedent.[8]
• CJC-1295 without DAC (Mod GRF 1-29) has minimal published clinical data. Most formal research uses the DAC version. No-DAC pharmacology is largely extrapolated from the parent GRF 1-29 sequence.
• Combination protocols (CJC-1295 + Ipamorelin) lack dedicated clinical trials. Synergy claims are mechanistically reasonable but clinically unconfirmed.
• Long-term safety surveillance is absent. The Teichman study was short-duration. Sigalos & Pastuszak’s safety review is encouraging but acknowledges the need for longer follow-up.[1][5]
• DAC vs no-DAC discussions are often over-simplified. The choice involves pharmacokinetic trade-offs, not categorical superiority.[1]

Decision rule: confidence is highest for GH/IGF-1 elevation in humans. Confidence decreases progressively for specific clinical outcomes, long-term safety, and combination protocol effects.

Verdict

CJC-1295 is one of the best-characterised GHRH analogs in the peptide research space, with human pharmacokinetic data demonstrating sustained GH/IGF-1 elevation and preserved pulsatile secretion. The compound has clear pharmacological advantages over both native GHRH (too short-lived) and exogenous GH (bypasses pituitary regulation).[1][2]

Where it fits: GH-axis support for recovery continuity, body composition maintenance, and aging-related GH decline contexts. It is not a fast-acting transformation agent — value is typically judged by trend quality across multi-week blocks when fundamentals (sleep, training, nutrition) are stable.

For navigation, map this profile to Muscle Growth, Fat Loss & Recomp, Longevity / Healthy Aging, and Hormonal Support. Pressure-test with CJC-1295 vs Ipamorelin and CJC-1295 vs Sermorelin, and cross-reference with Tesamorelin for the FDA-approved GHRH analog comparison and GHRP-2 for an alternative secretagogue pathway.

FAQ

What is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates pulsatile GH secretion from the anterior pituitary. In human studies, it produced sustained 2- to 10-fold GH increases and 1.5- to 3-fold IGF-1 increases lasting up to 6-11 days. It is one of the most studied GHRH analogs in the peptide research space.[1][2]

What does CJC-1295 peptide do?

CJC-1295 activates the GHRH receptor on pituitary somatotroph cells, triggering growth hormone synthesis and release while preserving natural pulsatile secretion patterns. The elevated GH drives hepatic IGF-1 production, which mediates downstream effects on recovery, body composition, and tissue repair.[1][2][3]

CJC-1295 with DAC vs without DAC: what is the practical difference?

The DAC (Drug Affinity Complex) enables covalent albumin binding, extending the half-life from ~30 minutes (no-DAC) to 5-8 days (with DAC). Both activate the same GHRH receptor. DAC provides sustained elevation with less frequent dosing; no-DAC provides sharper, shorter GH pulses. Neither is categorically superior — the choice depends on the research context.[1][4]

What are CJC-1295 benefits?

Documented benefits include sustained GH/IGF-1 elevation (2-10x GH, 1.5-3x IGF-1), preserved pulsatile secretion, extended duration of action, and potential support for recovery, body composition, and age-related GH decline. Downstream clinical benefits are supported by mechanism and class-level evidence but lack large-scale CJC-1295-specific outcome trials.[1][5][6]

What are CJC-1295 side effects?

Commonly reported side effects include injection site reactions, transient water retention, headache, flushing, and appetite changes. The Teichman study reported the compound was generally well tolerated. Glucose metabolism monitoring is appropriate with GH secretagogue use. Person-to-person variability is substantial.[1][5]

CJC-1295 dose and CJC-1295 dosage: why not listed here?

This page is informational only and does not provide dosing protocols. Dose and dosage intent is valid, but this profile focuses on mechanism context, evidence quality, and risk-aware interpretation. Refer to primary research literature for protocol parameters.

CJC-1295 vs Ipamorelin: why compare them?

CJC-1295 works via the GHRH receptor; Ipamorelin works via the ghrelin receptor (GHS-R). They stimulate GH through distinct pathways, which is why their combination is frequently discussed. No combination clinical trial exists, but the pharmacological rationale for synergy is sound. See CJC-1295 vs Ipamorelin.[5]

CJC-1295 vs Sermorelin: what is the useful decision angle?

Both are GHRH analogs, but CJC-1295 has amino acid modifications that resist enzymatic degradation and (with DAC) albumin binding for extended half-life. Sermorelin uses the native GRF(1-29) sequence with a very short half-life. CJC-1295 offers longer duration; Sermorelin has a longer clinical history. See CJC-1295 vs Sermorelin.

Is CJC-1295 safe?

The Teichman human study reported CJC-1295 was generally well tolerated with mostly mild injection-site adverse events. Sigalos & Pastuszak’s 2018 review concluded GH secretagogues as a class have acceptable safety profiles, while noting the need for longer-term surveillance. Long-term safety data specific to CJC-1295 remains limited.[1][5]

What is the CJC-1295 half-life?

With DAC: approximately 5-8 days (due to albumin binding). Without DAC (Mod GRF 1-29): approximately 30 minutes. For comparison, native GHRH has a half-life under 10 minutes. The DAC version represents roughly a 500-fold increase in persistence over native GHRH.[1][4]

Where does CJC-1295 map inside site goal pathways?

Most commonly to Muscle Growth, Fat Loss & Recomp, Longevity / Healthy Aging, and Hormonal Support. Interpreted with a trend-first, fundamentals-dependent lens rather than acute-effect expectations.

Is CJC-1295 the same as Modified GRF 1-29?

Not exactly. Modified GRF 1-29 (Mod GRF 1-29) refers to CJC-1295 without DAC — it has the same amino acid modifications for DPP-IV resistance but lacks the Drug Affinity Complex for albumin binding. CJC-1295 with DAC and Mod GRF 1-29 share the same core sequence but differ in half-life and administration characteristics.[1][4]

References

1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683.
2. Ionescu M, Bhatt DL. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID: 17018654.
3. Sackmann-Sala L, et al. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. PMID: 19386527.
4. Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. PMID: 15817669.
5. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28400207.
6. Sattler FR. Growth hormone in the aging male. Best Pract Res Clin Endocrinol Metab. 2013;27(4):541-555. PMID: 24054930.
7. Merriam GR, et al. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine. 2003;22(1):41-48. PMID: 14610297.
8. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a systematic review and meta-analysis. Obes Res Clin Pract. 2026;20(1):1-12. PMID: 41545261.
9. Merriam GR. Potential applications of GH secretagogs in the evaluation and treatment of the age-related decline in growth hormone secretion. Endocrine. 1997;7(1):49-52. PMID: 9449031.
10. Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026;54(1):223-229. PMID: 41476424.

If your query is what is ipamorelin, the practical answer is: ipamorelin is a synthetic growth hormone secretagogue (GHS) — a pentapeptide that stimulates growth hormone release by activating the ghrelin receptor (GHS-R1a) on pituitary somatotroph cells. What distinguishes ipamorelin from other GH secretagogues like GHRP-2 and GHRP-6 is its selectivity: it stimulates GH release without significantly elevating cortisol, ACTH, prolactin, or aldosterone.[1][2]

Raun et al. (1998) described ipamorelin as “the first selective growth hormone secretagogue” in European Journal of Endocrinology, documenting its ability to produce dose-dependent GH release comparable to GHRP-6 while avoiding the broader hormonal perturbations seen with earlier GH secretagogues.[1]

This selectivity profile is ipamorelin’s defining characteristic. While all GH secretagogues activate the ghrelin receptor to stimulate GH release, most also produce varying degrees of appetite stimulation, cortisol elevation, and aldosterone increases. Ipamorelin peptide achieves GH stimulation with minimal off-target hormonal effects, making it the cleanest GH secretagogue in terms of selectivity.[1][2][3]

For context within the GH-axis peptide class, ipamorelin works via a completely different receptor pathway than GHRH analogs like Sermorelin, CJC-1295, and Tesamorelin. While those compounds stimulate GH through the GHRH receptor, ipamorelin acts through the ghrelin/GHS receptor — making them mechanistically complementary rather than competitive.

Compound Profile

What Does Ipamorelin Actually Do?

Ipamorelin activates the ghrelin receptor (GHS-R1a) on anterior pituitary somatotroph cells, triggering pulsatile growth hormone release. The practical result is elevated GH and downstream IGF-1 levels achieved through a pathway that complements, rather than replaces, the body’s endogenous GHRH signalling.[1][2]

Key findings from published research:

• Selective GH release (Raun 1998): the foundational study demonstrated that ipamorelin produces dose-dependent GH release comparable to GHRP-6 in both in vitro pituitary cell cultures and in vivo animal models, but without affecting cortisol, ACTH, prolactin, or aldosterone levels — a selectivity advantage over all previously characterised GH secretagogues. Published in European Journal of Endocrinology.[1]
• Mechanistic distinction from GHRH (Ahnfelt-Rønne 2001): confirmed that GH-releasing peptides including ipamorelin act through the ghrelin/GHS receptor pathway rather than the GHRH receptor, establishing the mechanistic basis for dual-pathway GH stimulation when combined with GHRH analogs.[2]
• Bone growth stimulation (Johansen 1999): demonstrated that ipamorelin induces longitudinal bone growth in rats via GH-mediated IGF-1 elevation, supporting the connection between GH secretagogue-driven GH release and tissue-level anabolic effects.[4]
• Bone mineral preservation (Andersen 2001): showed ipamorelin counteracts glucocorticoid-induced decreases in bone formation in adult rats — evidence that GHS-mediated GH elevation can protect against catabolic bone loss.[5]
• Bone mineral content increase (Svensson 2000): ipamorelin and GHRP-6 both increased bone mineral content in adult female rats, demonstrating skeletal benefit from GH secretagogue stimulation.[6]

How Ipamorelin Works

Ipamorelin’s mechanism operates through the ghrelin receptor pathway — pharmacologically distinct from the GHRH receptor pathway used by sermorelin, CJC-1295, and tesamorelin.[1][2]

• GHS-R1a activation: ipamorelin binds the growth hormone secretagogue receptor type 1a (GHS-R1a, also known as the ghrelin receptor) on pituitary somatotroph cells. This triggers intracellular calcium signalling and IP3/DAG pathways, leading to GH granule release.[1][2]
• Selectivity mechanism: unlike GHRP-2 and GHRP-6, ipamorelin does not significantly activate other pituitary hormone pathways. It does not elevate ACTH (which drives cortisol), prolactin, or aldosterone at GH-stimulating doses. This selectivity is attributed to its specific receptor binding profile — strong GHS-R1a affinity without meaningful activation of other receptor subtypes.[1]
• Complementary to GHRH pathway: GH release from somatotrophs is regulated by two opposing signals: GHRH (stimulatory) and somatostatin (inhibitory). GH secretagogues like ipamorelin work through a third, independent pathway (GHS-R1a), amplifying GH release even when GHRH signalling is moderate. This is why ipamorelin CJC-1295 combinations are frequently discussed — they stimulate GH through two separate receptor pathways simultaneously.[2][7]
• Pulsatile release preserved: ipamorelin triggers discrete GH pulses rather than continuous elevation, maintaining the body’s natural secretory rhythm and somatostatin-mediated feedback.[1][3]

The dual-pathway concept: when combined with a GHRH analog (CJC-1295 or sermorelin), ipamorelin provides GHS-R1a stimulation while the GHRH analog provides GHRH receptor stimulation. This dual input to the somatotroph cell is theorised to produce a synergistic GH response greater than either pathway alone — though formal head-to-head clinical trials of the combination are limited.[2][7][8]

Recovery and Sleep Context

Recovery and sleep is one of ipamorelin’s most practically relevant domains, through its role in augmenting nocturnal GH pulses.

• GH-sleep relationship: the largest natural GH pulse occurs during slow-wave (deep) sleep. Jessup et al. (2004) demonstrated the specific mechanistic link between GH-releasing pathways and nocturnal GH secretion. GH secretagogue stimulation amplifies this natural pulse, supporting tissue repair and protein synthesis during sleep.[9]
• Recovery quality: elevated nocturnal GH supports glycogen replenishment, tissue repair, and immune function during sleep. Ipamorelin users most consistently report improved recovery quality upon waking and better readiness between training sessions.
• Clean sleep augmentation: ipamorelin’s selectivity advantage is relevant here — it doesn’t elevate cortisol (which would disrupt sleep architecture) or stimulate appetite significantly (which would be counterproductive at bedtime). This makes it the cleanest GH secretagogue for evening/bedtime use targeting sleep-linked recovery.[1][3]

Practical interpretation: ipamorelin’s value for recovery is through GH-mediated physiological processes during sleep, not as a sleep aid per se. Track recovery quality and training readiness over 4+ week blocks rather than expecting immediate single-night effects.

Body Composition and Muscle Growth Context

Muscle growth and body composition relevance for ipamorelin operates through the GH/IGF-1 axis. The evidence base is primarily preclinical and mechanistic, with supporting context from GH secretagogue class reviews.[1][7][8]

• GH-driven anabolic signalling: ipamorelin-stimulated GH release drives hepatic IGF-1 production, which supports protein synthesis, nitrogen retention, and muscle repair. The effect is indirect — ipamorelin stimulates GH, which stimulates IGF-1, which supports anabolic processes.[1]
• Body composition management: Sinha et al. (2020) reviewed GH secretagogues as body composition tools in hypogonadal men, noting their role in supporting lean mass maintenance and fat reduction alongside other interventions.[8]
• Bone health support: Johansen (1999) and Andersen (2001) demonstrated that ipamorelin promotes bone growth and counteracts glucocorticoid-induced bone loss in animal models — supporting the broader musculoskeletal benefit of GH secretagogue-mediated GH elevation.[4][5]
• Recovery-driven training adaptation: the primary muscle growth mechanism is through improved recovery between training sessions, enabling higher training consistency, volume tolerance, and adaptation over time.

Honest assessment: ipamorelin is a recovery and hormonal environment support compound, not a direct muscle builder. The ipamorelin benefits for body composition are most visible when training, nutrition, and sleep fundamentals are already well-established. Expect gradual improvements in recovery quality and body composition trends over weeks, not rapid transformation.

Fat Loss and Body Recomp Context

Fat loss and body recomposition with ipamorelin operates through GH’s lipolytic effects. Growth hormone promotes fatty acid mobilisation from adipose tissue and shifts substrate utilisation toward fat oxidation.

• GH-driven lipolysis: elevated GH levels promote the breakdown and mobilisation of stored triglycerides. The effect is gradual and most visible in body composition ratios (lean mass to fat mass) rather than dramatic scale weight changes.[7][8]
• Cortisol advantage: unlike GHRP-2 and GHRP-6, ipamorelin does not elevate cortisol — a catabolic hormone that promotes fat storage (particularly visceral fat) and muscle breakdown. This selectivity makes ipamorelin theoretically more favourable for body recomposition goals.[1][3]
• Appetite neutrality: GHRP-6 and ghrelin itself strongly stimulate appetite, which can counteract fat loss efforts. Ipamorelin’s appetite effect is minimal, making it easier to maintain caloric targets during fat loss phases.[1]

Practical framing: ipamorelin supports fat loss through hormonal environment optimisation rather than direct metabolic acceleration. For dedicated fat loss, compounds like semaglutide or tirzepatide have dramatically stronger direct evidence. Ipamorelin’s role in fat loss is as a support compound within a broader strategy.

Hormonal Support Context

Testosterone and hormonal support with ipamorelin is indirect. Ipamorelin acts exclusively on the GH axis via GHS-R1a, not the HPG axis that governs testosterone production.[1][2]

However, adequate GH signalling supports the broader endocrine environment. Sinha et al. (2020) specifically positioned GH secretagogues as adjuncts in hypogonadal management — noting that optimising the GH axis supports body composition, recovery, and metabolic health, all of which contribute to overall hormonal wellbeing.[8]

Merriam et al. (2003) reviewed GH secretagogues in the context of normal aging, noting that somatopause compounds GH decline alongside other age-related endocrine changes. Addressing GH-axis decline may complement other interventions targeting the broader hormonal landscape.[7]

The honest framing: ipamorelin is a GH-axis compound with possible indirect hormonal environment benefits. For dedicated testosterone or hormonal support, it is best evaluated as part of a multi-modal approach rather than a standalone solution.

Ipamorelin CJC-1295 Combination

The ipamorelin CJC-1295 combination (search volume: 2,400+) is one of the most frequently searched pairings in the GH peptide space. The rationale is dual-pathway GH stimulation:

• Ipamorelin: activates GHS-R1a (ghrelin receptor pathway)
• CJC-1295: activates the GHRH receptor pathway

These are independent receptor systems on the same pituitary somatotroph cell. The theoretical basis for synergy is that stimulating both inputs simultaneously produces greater GH release than either alone — an effect documented for GHRH + GHS-R1a agonist combinations in neuroendocrine research.[2][7]

Important caveat: while the pharmacological rationale for synergy is sound, formal clinical trials specifically evaluating the ipamorelin + CJC-1295 combination in human subjects are limited. The combination is widely used based on mechanistic reasoning and individual compound evidence rather than dedicated combination trial data. See CJC-1295 vs Ipamorelin for the detailed comparison.

Ipamorelin Benefits

Ipamorelin benefits are best understood through the selectivity lens that distinguishes it from other GH secretagogues:

• Selective GH release: produces dose-dependent GH elevation without raising cortisol, ACTH, prolactin, or aldosterone — the cleanest GH secretagogue selectivity profile documented.[1]
• Recovery and sleep support: amplification of nocturnal GH pulses supports tissue repair, protein synthesis, and recovery quality during sleep.[9]
• Body composition support: GH-mediated improvements in lean mass maintenance and fat mobilisation, without the appetite stimulation that complicates fat loss with other GH secretagogues.[1][8]
• Bone health support: preclinical evidence demonstrates bone growth stimulation, increased bone mineral content, and protection against glucocorticoid-induced bone loss.[4][5][6]
• Minimal cortisol impact: does not elevate cortisol, preserving sleep architecture and avoiding the catabolic, fat-storing effects of cortisol elevation.[1][3]
• Minimal appetite stimulation: unlike GHRP-6 and ghrelin, ipamorelin does not significantly increase appetite — practical for maintaining caloric targets.[1]
• Complementary to GHRH analogs: works through a separate receptor pathway, enabling theoretical synergy with CJC-1295, sermorelin, or tesamorelin.[2][7]
• Good safety profile: Sigalos & Pastuszak (2018) reviewed GH secretagogues and confirmed acceptable safety profiles as a class.[3]

Ipamorelin Side Effects

For ipamorelin side effects intent, the safety profile benefits from the same selectivity that defines the compound’s advantages:

• Injection site reactions: redness, swelling, or discomfort at the injection site. The most commonly reported adverse effect.[3]
• Head rush or flushing: transient warmth or light-headedness shortly after injection, typically resolving within minutes.[3]
• Headache: occasional, usually mild and transient.[3]
• Water retention: mild fluid retention is possible with sustained GH elevation. Generally less pronounced than with exogenous GH.[3][10]
• Tingling or numbness: paraesthesia can occur with elevated GH/IGF-1 levels, typically mild.[3]

What ipamorelin does not typically cause (distinguishing it from other GH secretagogues):

• No significant cortisol elevation — unlike GHRP-2 and GHRP-6[1]
• No significant appetite stimulation — unlike GHRP-6 and ghrelin[1]
• No significant prolactin elevation — unlike GHRP-2[1]

Sigalos & Pastuszak (2018) reviewed GH secretagogues as a class and concluded they have acceptable safety profiles, though long-term surveillance data specifically for ipamorelin remains limited given its investigational status.[3]

Half-Life

Ipamorelin has an estimated half-life of approximately 2 hours after subcutaneous injection. This places it in the middle range for GH secretagogues — substantially longer than native ghrelin but shorter than modified GHRH analogs.[1][3]

For comparison across GH-axis peptides:

• Native ghrelin: approximately 30 minutes
• Sermorelin (GRF 1-29): approximately 10-20 minutes
• Ipamorelin: approximately 2 hours
• Tesamorelin: approximately 26 minutes
• CJC-1295 (no DAC): approximately 30 minutes
• CJC-1295 (with DAC): approximately 5-8 days

The ~2-hour half-life means ipamorelin produces a defined GH pulse followed by clearance — maintaining the pulsatile pattern that distinguishes secretagogue-mediated GH elevation from continuous exogenous GH. Evening/bedtime administration aligns the GH pulse with the natural nocturnal GH surge.[1][9]

Limits of Current Evidence

• No FDA approval. Ipamorelin has never been approved for any indication in any country. It remains investigational.[1][3]
• Evidence base is predominantly preclinical. The foundational selectivity data (Raun 1998) and the bone studies (Johansen 1999, Andersen 2001, Svensson 2000) are animal studies. Large-scale human clinical trials are lacking.[1][4][5][6]
• No dedicated human body composition trials. Unlike tesamorelin (which has JAMA and Lancet HIV RCTs), ipamorelin lacks published human trials specifically measuring body composition outcomes.
• Combination synergy is theoretical. The ipamorelin + CJC-1295 combination is widely used but lacks dedicated clinical trial evidence. The synergy rationale is based on dual-pathway receptor pharmacology, not direct combination studies.[2][7]
• Long-term safety data limited. The available safety data comes from relatively short-term preclinical studies and the GH secretagogue class review. Multi-year human safety data is not available.[3]
• GH secretagogue tachyphylaxis. Some GH secretagogues show reduced GH response with continuous long-term use. Whether this affects ipamorelin specifically, and to what degree, is not well-characterised in published literature.

Decision rule: ipamorelin has a well-characterised selectivity profile (the cleanest of any GH secretagogue) supported by quality preclinical data. Its practical limitation is the gap between the strong mechanistic/pharmacological rationale and the relative absence of large-scale human clinical trials. Positioning should reflect this evidence level honestly.

Verdict

Ipamorelin is the most selective growth hormone secretagogue characterised in the published literature — a compound that stimulates robust GH release through the ghrelin receptor pathway without the cortisol, appetite, prolactin, and aldosterone effects seen with earlier GH secretagogues like GHRP-2 and GHRP-6.[1]

Its selectivity profile makes it the cleanest GH secretagogue for contexts where avoiding hormonal side effects matters — particularly recovery and sleep support (no cortisol disruption), body composition management (no appetite stimulation), and combination use with GHRH analogs (complementary rather than overlapping pathway).[1][2][3]

The honest limitation: ipamorelin’s evidence base is predominantly preclinical. The selectivity data is well-established, but dedicated human clinical trials for body composition, recovery, or performance outcomes are lacking. Users should understand they are working with strong pharmacological rationale and established selectivity data rather than large-scale clinical proof.

For navigation, map this profile to Recovery & Sleep, Muscle Growth, Fat Loss & Recomp, and Hormonal Support. Pressure-test with Ipamorelin vs Sermorelin, CJC-1295 vs Ipamorelin, Ipamorelin vs Tesamorelin, and Ipamorelin vs MK-677, and cross-reference with GHRP-2 for the less-selective GH secretagogue comparison.

FAQ

What is ipamorelin?

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that stimulates GH release by activating the ghrelin receptor (GHS-R1a). It is described as “the first selective growth hormone secretagogue” because it elevates GH without significantly affecting cortisol, ACTH, prolactin, or aldosterone. It is not FDA-approved and remains investigational.[1]

What does ipamorelin peptide do?

Ipamorelin activates ghrelin receptors on pituitary somatotroph cells, triggering pulsatile growth hormone release. This elevated GH drives IGF-1 production, which supports tissue repair, recovery, body composition (lean mass maintenance, fat mobilisation), bone health, and sleep-linked recovery processes. Its key distinction is achieving these GH effects without raising cortisol or stimulating appetite.[1][2]

What are ipamorelin benefits?

Key benefits include selective GH release without cortisol/appetite/prolactin elevation, recovery and sleep quality support through nocturnal GH amplification, body composition support, bone health enhancement, and complementarity with GHRH-pathway peptides (CJC-1295, sermorelin). The selectivity profile makes it the cleanest GH secretagogue available.[1][3][4]

What are ipamorelin side effects?

Common side effects include injection site reactions, transient flushing, headache, mild water retention, and occasional tingling. Notably, ipamorelin does NOT significantly elevate cortisol, stimulate appetite, or raise prolactin — side effects common with other GH secretagogues like GHRP-2 and GHRP-6. Overall safety profile is considered acceptable based on available data.[1][3]

Ipamorelin dose and ipamorelin dosage: why not listed here?

This page is informational only and does not provide dosing protocols. Ipamorelin is an investigational compound not approved for any indication. This profile focuses on mechanism context, evidence quality, and risk-aware interpretation.

Ipamorelin CJC-1295: why are they often combined?

They stimulate GH through completely different receptor pathways: ipamorelin via GHS-R1a (ghrelin receptor), CJC-1295 via the GHRH receptor. Dual-pathway stimulation is theorised to produce synergistic GH release greater than either alone. The combination is widely used but lacks dedicated clinical combination trials. See CJC-1295 vs Ipamorelin.[2][7]

Ipamorelin vs sermorelin: which is better?

“Better” depends on priorities. Ipamorelin is more selective (no cortisol/appetite effects) with a longer half-life (~2h vs ~15min). Sermorelin has a historical FDA approval and longer clinical safety record. They work through different receptors and can theoretically be combined. See Ipamorelin vs Sermorelin for the full comparison.[1]

Is ipamorelin FDA approved?

No. Ipamorelin has never been FDA-approved for any indication. It remains an investigational compound. Unlike sermorelin (historical Geref® approval) and tesamorelin (current Egrifta® approval), ipamorelin has not gone through the regulatory approval process.[1][3]

How long does ipamorelin take to work?

GH elevation occurs within 15-30 minutes of injection. IGF-1 increases develop over days. Recovery and body composition improvements typically become noticeable over 4-8 weeks with consistent use. Judge results by multi-week trends in recovery quality and body composition rather than single-day impressions.

Does ipamorelin stimulate appetite?

Minimally, if at all. This is one of ipamorelin’s key advantages over other GH secretagogues. GHRP-6 strongly stimulates appetite (via ghrelin pathway activation), while ipamorelin achieves comparable GH release with minimal appetite effects. This makes it more practical for body composition and fat loss contexts.[1]

Can ipamorelin be used with other peptides?

Ipamorelin is commonly discussed in combination with GHRH-pathway peptides (CJC-1295, sermorelin) based on the dual-receptor-pathway synergy rationale. The compounds target different receptors on the same pituitary cell type, making them mechanistically complementary. However, dedicated clinical combination studies are limited.[2][7]

What should be tracked when evaluating ipamorelin?

Recovery quality upon waking, training readiness between sessions, sleep quality impressions, body composition trends (ideally via DEXA or calibrated measurements), and overall energy levels. Track across 4+ week blocks with controlled training and nutrition. Single-day assessments are unreliable due to many confounding variables.

References

1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822.
2. Ahnfelt-Rønne I, et al. Do growth hormone-releasing peptides act as ghrelin secretagogues? Endocrine. 2001;14(1):133-135. PMID: 11322495.
3. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28400207.
4. Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. PMID: 10373343.
5. Andersen NB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001;11(5):266-272. PMID: 11735244.
6. Svensson J, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569-577. PMID: 10828840.
7. Merriam GR, et al. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine. 2003;22(1):41-48. PMID: 14610297.
8. Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. PMID: 32257855.
9. Jessup SK, et al. Blockade of endogenous growth hormone-releasing hormone receptors dissociates nocturnal growth hormone secretion and slow-wave sleep. Eur J Endocrinol. 2004;151(5):561-566. PMID: 15538933.
10. Sattler FR. Growth hormone in the aging male. Best Pract Res Clin Endocrinol Metab. 2013;27(4):541-555. PMID: 24054930.
11. Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026;54(1):223-229. PMID: 41476424.